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Astrocytes are critical for the well-
being of neurons, both in health 
and neuropathological conditions. 
However, their involvement in 
the degradation of neurotoxic 
beta-amyloid (Aβ) in Alzheimer’s 
disease (AD) has remained largely 
unresolved. This thesis reveals 
important factors related to the 
maturation stages of astrocytes, how 
they respond to and their capacity to 
degrade different forms of human Aβ 
aggregates as well as their interplay 
with microglia in experimental 
models of AD.
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ABSTRACT 
 
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder and the 
most common form of dementia. In AD, aggregated, cytotoxic β-amyloid (Aβ) peptides 
impair neuronal function and lead to a decline in memory and other cognitive functions. 
Other pathological hallmarks are intracellular neurofibrillary tangles, neuroinflammatory 
condition of Aβ-associated activated glial cells and severe neuronal and synaptic loss. 
Astrocytes and microglia are the most abundant glial cells in the brain being involved in 
homeostasis and they regulate numerous immunomodulatory and neurotrophic functions. 
They also share the capacity of being able to degrade Aβ. Adult astrocytes can break down 
Aβ spontaneously in vitro and ex vivo whereas the capacity of microglia for this effect is 
very limited without specific stimulation. Furthermore, the evidence for astrocyte-mediated 
Aβ degradation in vivo has remained inadequate. 
The present thesis focused on the role of astrocytes in the clearance of Aβ in 
experimental models of AD. Cultured adult mouse astrocytes were found to significantly 
reduce the Aβ burden in human AD brain sections, in contrast to the situation in neonatal 
astrocytes. However, after 1-7 days’ follow-up time, both transplanted adult and neonatal 
astrocytes internalized Aβ deposits in the hippocampi of an Aβ-overproducing AD mouse 
model (APdE9).  
Mature astrocytes were also transplanted into 12 month and 23-24-month-old APdE9 
mouse hippocampi. After a two months’ follow-up time, the Aβ burden was significantly 
reduced in astrocyte-transplanted APdE9 mice compared to PBS-injected APdE9 mice. 
Numerous transplanted astrocytes had taken up Aβ, become apoptotic and were 
surrounded by phagocytic microglia. The transplanted astrocytes also expressed Aβ 
degrading proteases neprilysin, angiotensin-converting enzyme-1 and endothelin 
converting enzyme-2. These proteases were confirmed to be involved in Aβ degradation by 
adult astrocytes as assessed in an ex vivo assay. Surprisingly, the proteases spontaneously 
secreted from both neonatal and adult astrocytes efficiently degraded synthetic Aβ1-42. 
These proteases belonged to the serine protease family, but in neonatal astrocytes, also 
secreted metalloproteases and aspartyl peptidases degraded Aβ1-42 to some extent.  
Finally, differences in gene expression profiles between adult and neonatal astrocytes 
were examined after growing the cells on APdE9 or wild-type brain sections. The number 
of genes with altered expression was notably greater in adult astrocytes; in these cells some 
of the up-regulated genes related to Aβ degradation, endocytosis and anti-oxidative 
function in response to APdE9 section. qRT-PCR analysis confirmed the alteration in gene 
expression of key Aβ degrading peptidases, scavenger receptors and cholesterol synthesis. 
The thesis clarifies the role of astrocytes as cells contributing to Aβ catabolism in AD like 
conditions and reveals important factors related to maturation stages of astrocytes and their 
responses to different forms of human Aβ aggregates. Astrocytes are capable of 
substantially clearing Aβ from the brain, i.e. astrocyte-mediated Aβ clearance may 
represent a potential therapeutic strategy for AD.  
National Library of Medical Classification:  QY 60.R6, WL 101-102, WT 115 
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TIIVISTELMÄ  
 
Alzheimerin tauti (AT) on ikääntymiseen liittyvä etenevä hermorappeumatauti ja yleisin 
dementian muoto. AT:ssa sakkautuneet β-amyloidi- (Aβ) peptidit vahingoittavat 
hermosoluja, johtaen muistin ja muiden kognitiivisten toimintojen rappeutumiseen. Muita 
patologisia tunnusmerkkejä ovat hermosolujen fibrillikimput, aivokudoksen tulehdustila, 
gliasolujen liittyminen Aβ:n yhteyteen sekä selvä hermosolu- ja synapsikato. 
Astrosyytit ja mikrogliat ovat yleisiä gliasoluja, jotka tukevat hermoston toimintaa, 
ylläpitävät homeostaasia ja säätelevät immuunivastetta aivoissa. Nämä solut hajottavat 
lisäksi Aβ:a. Aikuisesta hiirestä eristetyt astrosyytit hajottavat sakkautunutta Aβ:aa 
spontaanisti, mikrogliojen vaatiessa tähän erityistä stimulaatiota. Kuitenkin todisteet 
astrosyyttien Aβ:n hajotuksesta AT:n eläin- ja solumalleilla ovat vielä riittämättömiä. 
Väitöskirja käsittelee astrosyyttien roolia Aβ:n hajottajina AT:n tautimalleissa. Aikuisen 
hiiren astrosyyttien havaittiin vähentävän merkittävästi Aβ:a AT-potilaan post-mortem 
aivoleikkeistä, kun taas vastasyntyneen hiiren astrosyytit eivät tähän kyenneet. Kun 
aikuisen ja vastasyntyneen astrosyyttejä siirrettiin Aβ:aa yli-ilmentävän AT-hiiren (APdE9) 
aivojen hippokampukseen, molemmat solutyypit ottivat Aβ:a sisäänsä 1-7 päivän kuluessa. 
Kun aikuisen hiiren astrosyyttejä siirrettiin 12 kk ja 23-24 kk vanhojen AT-hiirten 
hippokampuksiin, Aβ:n määrä väheni merkittävästi astrosyyttisiirretyissä hiirissä jo 
kahden kuukauden kuluessa verrattuna fysiologisella suolaliuoksella hoidettuihin 
verrokkeihin. Siirretyt astrosyytit hajottivat nuorempien hiirten lievemmin sakkautunutta 
Aβ:a tehokkaammin kuin vanhojen hiirten tiiviitä Aβ-plakkeja, mutta tämän seurauksena 
kuitenkin kuolivat. Aivojen solujätteen puhdistamisesta vastaavat mikrogliat kerääntyivät 
kuolevien astrosyyttien yhteyteen. Siirretyt astrosyytit tuottivat Aβ:a hajottavia proteaaseja, 
neprilysiiniä, angiotensiini-1-konvertaasia ja endoteliini-2-konvertaasia. Samat proteaasit 
osallistuivat Aβ:n hajotukseen, kun AT-hiireltä peräisin olevan aivoleikkeen päällä 
kasvatettiin aikuisen astrosyyttejä. Yllättäen, sekä aikuisen että vastasyntyneen 
astrosyyteistä spontaanisti ulos eritetyt, lähinnä seriiniproteaasiperheen entsyymit 
hajottivat tehokkaasti synteettistä Aβ1-42:a. Vastasyntyneen astrosyyteillä Aβ1-42:n 
hajoittamisesta vastasivat osin myös metalloproteaasit ja aspartyylipeptidaasit. 
Geenien ilmentymisen eroja määritettiin AT-hiiren ja terveen kontrollihiiren 
aivoleikkeiden päällä kasvatettujen aikuisen ja vastasyntyneen astrosyyttien välillä. 
Ilmentymiseltään muuttuneiden geenien määrä oli suurempi aikuisen astrosyyteillä, mm. 
Aβ-hajoitukseen, endosytoosiin ja anti-oksidatiivisiin toimintoihin liittyvien geenien 
ilmentyminen lisääntyi. Kvantitaatio-analyysi varmisti muutokset tärkeimpien Aβ:a 
hajoittavien peptidaasien, jätteidenkeräilijäreseptorien ja kolesterolisynteesin osalta. 
Väitöskirja selventää astrosyyttien roolia Aβ:n hajoittajina AT:a muistuttavissa 
olosuhteissa, osoittaen tärkeitä tekijöitä astrosyyttien eri kypsyysasteiden vasteissa 
ihmisperäisen Aβ:n eri muotoja kohtaan. Astrosyyttien kykyä hajottaa tehokkaasti 
Alzheimerin taudissa kertyvää Aβ:tä voi olla mahdollista hyödyntää AT-potilaiden 
terapiassa. 
 
Luokitus: QY 60.R6, WL 101-102, WT 115 
Yleinen Suomalainen Asiasanasto: aivot; Alzheimerin tauti; hermosto; hippokampus; neurobiologia 
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 1 Introduction 
The amyloid cascade hypothesis proposes that the production and deposition of neurotoxic 
beta-amyloid (Aβ) underlies Alzheimer’s disease (AD) (Hardy and Higgins 1992; Selkoe 
1991b). Probably the strongest evidence in support of this amyloid-centered hypothesis 
arises from the inherited, familial forms of AD, where mutations in genes encoding 
neurotoxic Aβ-producing amyloid precursor protein (APP) (Tanzi et al. 1987), presenilin 1 
(PSEN1) (Sherrington et al. 1995; Sisodia and St George-Hyslop 2002) or presenilin 2 
(PSEN2) (Levy-Lahad et al. 1995) induce the accumulation of Aβ deposits, and together 
with the other typical hallmarks of AD (neurofibrillary tangles, inflammation), evoke the 
degeneration of neurons, severe cognitive deficits and ultimately the death of the patient 
(Hardy and Selkoe 2002; Massoud and Gauthier 2010). Late-onset, sporadic AD manifests 
similar pathological characteristics and clinical symptoms despite the lack of the genetic 
factors above. Thus, the amyloid cascade hypothesis strongly supports the involvement of 
Aβ accumulation also in sporadic AD. 
At present, in addition to overproduction of Aβ, inefficient clearance of Aβ deposits is 
considered a key phenomenon in the amyloid cascade hypothesis (Hardy and Selkoe 2002). 
There are recent findings that certain, non-fibrillar oligomeric forms of Aβ are extremely 
neurotoxic (Nielsen et al. 2009, 2010; Walsh and Selkoe 2007). Nevertheless, the evidence in 
favour of the neurotoxicity of different forms of Aβ is still rather conflicting, partly due to 
the technical challenges in assessing this phenomenon (Rahimi et al. 2008). Even though 
there is uncertainty about the most toxic Aβ species, the amyloid cascade hypothesis 
proposes that a reduction in the levels of total Aβ might help halt the progression of AD. 
The first treatments based on the amyloid cascade hypothesis and Aβ reduction strategy, 
e.g. monoclonal antibodies against Aβ and secretase inhibitors, have reached Phase III 
clinical trials (Massoud and Gauthier 2010). Understanding the contribution of different 
CNS cell types in Aβ production and clearance is therefore of the utmost importance.  
Astrocytes are brain glial cells which perform many fundamental tasks, ranging from the 
maintenance of ionic homeostasis, the regulation of the neurotransmitter levels in synaptic 
clefts, the control of cerebral blood flow to the maintenance of the fine-tuned glucose levels 
in the brain (Farina et al. 2007). In addition, astrocytes are involved in immunomodulatory 
functions in the brain, a function that they share with microglia, secreting both pro- and 
anti-inflammatory cytokines. Thus, functional defects or atrophy of astroglia during aging 
and several neuropathological conditions, including AD, may have negative impacts on the 
neurons they support (Chvátal et al. 2008; Verkhratsky et al. 2010). During recent years, it 
has been shown in several studies that astrocytes efficiently degrade different forms of Aβ 
in vitro and ex vivo, without stimulation (Koistinaho et al. 2004; Nielsen et al. 2009, 2010; 
Wegiel et al. 2000; Wyss-Coray et al. 2003) but the evidence for their role in Aβ degradation 
in vivo has still remained inadequate. However, it is conceivable that the atrophy or 
functional defects attributable to the pathological changes associated with aging (e.g. 
inflammation) impair the ability of endogenous astrocytes to clear Aβ. It has even been 
hypothetized that AD or chronic stress may be able to convert astrocytes from Aβ 
degrading cells into Aβ producers, a function which normally is neuron-specific (Rossner et 
al. 2005; Heneka et al. 2005a).  
Enzymes called proteases and peptidases are involved in the degradation of any protein 
or peptide, including Aβ. A remarkable number (2 %) of genes in the genome encode 
proteases, indicating that proteolysis plays an important role in human biology (Puente et 
al. 2005). Over the past years, numerous proteins have been shown to have a key role in Aβ 
production and clearance, but considerable controversy exists regarding their precise 
functions and mechanisms. Further elucidations of these mechanisms are therefore needed, 
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as they possibly can represent new therapeutic strategies to reduce Aβ accumulation and 
increase its clearance and thus combat AD. 
The purpose of this thesis was to broaden the understanding of astrocytes as Aβ 
degrading cells and to observe how the maturation of astrocytes can affect their Aβ 
degradation capabilities. This thesis investigates the ability of healthy astrocytes at different 
maturation stages to recognize, internalize and degrade human Aβ using ex vivo and in vivo 
methods relevant for AD. To further define the specific mechanisms during the Aβ 
degradation process ex vivo and in vivo, the expression of Aβ degrading proteases was 
evaluated ex vivo and in vivo and also performed a whole-genome wide gene array analysis 
from the adult and neonatal astrocytes exposed to Aβ ex vivo.  
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2 Review of Literature  
2.1 ALZHEIMER’S DISEASE (AD) 
2.1.1 Clinical features and neuropathology of Alzheimer’s disease 
The German doctor Alois Alzheimer first described the pathological and clinical symptoms 
of a devastating neurodegenerative disorder from a middle aged woman in 1907 
(Alzheimer 1907) documenting the classical pathology of AD: neurofibrillary tangles and 
senile plaques in the neocortex and hippocampus. Aβ deposition first destroys the 
hippocampal nerve cells, impairing the short-term memory and the ability to perform easy 
and familiar tasks (Massoud and Gauthier 2010). Later, the pathology extends to the 
cerebral cortex causing abnormalities in problem solving, calculation, judgement and 
language skills, visuospatial perceptions and possibly also changes in personality. As the 
brain atrophy proceeds, the patient becomes mute, incontinent, bedridden and 
unresponsive to the outside world, and these can be followed by an immunodeficiency 
(McKhann et al. 1984). The most common cause of death is a disease of the respiratory or 
circulatory system (Brunnström and Englund 2009). The age at diagnosis is the most 
important factor for the estimate of survival time (Helzner et al. 2008). Brookmeyer et al. 
(2002) showed that survival time was seven to ten years for the patients diagnosed at the 
age of 60 into their early 70s but only three years for patients diagnosed in their 90s. Other 
factors may also affect the survival time, e.g. gender, employment, preceding dietary habits 
and health status (Reynish et al. 2001; Scarmeas et al. 2005). In 2010, over 24 million AD 
cases were registered worldwide, and by 2040 it is estimated that this figure will rise to 
over 80 million (Massoud and Gauthier 2010). The increasing number of the patients is due 
to overall aging of the population, but it is noteworthy that the largest increases in 
population and life expectancy are predicted to occur in developing countries (Mount and 
Downton 2006). In the early stage of AD, some medical treatments may delay the 
symptoms but they do not halt progression of this disease. 
Similar to Parkinson’s, Huntington’s and prion diseases, AD is also associated with 
aggregations and conformational alterations in proteins, including Aβ, tau, lipotransport 
protein apolipoprotein E and the presynaptic protein α-synuclein (Mucke 2009). The 
aggregated, deposited forms of Aβ are believed to play one of the most important roles in 
the AD pathogenesis (Wisniewski and Konietzko 2008), but also soluble Aβ oligomers, 
especially dimers, extracted from AD brains efficiently impair synapse structure and 
function (Shankar et al. 2008). After this damage to neurons, astrocytes and microglia, the 
two main glial cells of the CNS, trigger a complex sense of neuropathological processes by 
producing various inflammatory factors (e.g. cytokines interleukin-1 (IL-1), IL-6, tumor 
necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), complement 
proteins, acute-phase reactants and various proteases) and therefore further promote AD 
pathogenesis (Cacquevel et al. 2004). 
Other possible factors contributing to the development of AD include environmental 
exposures, for example to certain neurotoxic metals (e.g. aluminum, zinc, lead) 
(Shcherbatykh and Carpenter 2007) or pesticides (Bosma et al. 2000). Furthermore, head 
injuries, stroke, high blood pressure, high blood cholesterol levels (Kivipelto et al. 2001), 
hyperlipidemia and hyperglycemia (Fernández et al. 2008; Rönnemaa et al. 2008) and 
obesity (Whitmer et al. 2005) are potential risk factors. In addition, certain infectious factors, 
like herpes simplex virus (HSV) antibodies may be present at higher levels in some AD 
patients as compared to healthy individuals (Letenneur et al. 2008).  
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2.1.2 Genetic factors related to Alzheimer’s disease 
AD is a genetically complex disease which can be divided into two distinct groups: early-
onset familial AD (EOFAD, onset age < 65 yrs) and late-onset AD (LOAD, onset age > 65 
yrs). Only 5% of AD cases are EOFAD. The inherited mutations currently identified are in 
genes encoding amyloid precursor protein (APP; gene APP) (Tanzi et al. 1987), presenilin 1 
(PS1; gene PSEN1) (Sherrington et al. 1995; Sisodia and St George-Hyslop 2002) or 
presenilin 2 (PS2; gene PSEN2) (Levy-Lahad et al. 1995).  
LOAD involves both genetic and non-genetic factors, thus being a notably more 
complicated form of AD. At present, APOE-protein producing gene APOE has been 
convincingly shown to be associated with an increased risk for LOAD (Strittmatter et al. 
1993) – the allele ε4 increases the risk of suffering AD and decreases the age of AD onset in 
an allele dose-dependent manner (Blacker et al. 1997). APOE is involved in AD 
pathogenesis by affecting Aβ metabolism and aggregation as well as directly regulating 
brain lipid metabolism (Bu 2009), but the presence of the ε4 allele is not necessary or 
sufficient for the development of AD (Waring and Rosenberg 2008). In addition, A2M 
encoding the plasma protein α2-macroglobulin (α2M), which binds and degrades soluble 
Aβ is associated with LOAD (Kovacs 2000). New potential positional or functional AD 
genes appear with increasing pace and the genetic variation of AD is high (Hiltunen et al. 
2011). The AD-related genetic loci have other effects e.g. on disease onset, blood pressure, 
brain atrophy, cerebrovascular perfusion, Aβ deposition and clearance, apoE secretion, 
lipid metabolism, cognition and  apoptosis (Hollingworth et al. 2011).  
2.1.3 APP processing and function 
The generation of different Aβ isoforms from amyloid precursor protein (APP) is a 
fundamental and constitutive event in the CNS. In AD, however, the overproduction or 
deficient clearance mechanisms lead to the accumulation and aggregation of Aβ causing 
synaptic failure and neurotoxicity. Recently, it has been noted that the level of aggregation 
may determine the toxicity of Aβ. 
APP is a type I transmembrane protein (Stolt and Bock 2006), which can be alternatively 
spliced into different splice variants of different lengths. The most relevant variants to AD 
are APP695 expressed only in the CNS and APP751 and the full-length APP770, expressed 
in peripheral and CNS tissues (Kang and Muller-Hill 1990; Kitaguchi et al. 1988; Tanzi et al. 
1988). All of these forms contain full-length Aβ peptide which can be processed into the 
amyloidogenic Aβ. For example, in cultured rat CNS cells the splicing is cell-specific, 
neurons expressing mainly the form APP695 and astrocytes APP770 and APP751 (Rohan de 
Silva et al. 1997). APP possesses functional domains, for example an N-terminal signal 
peptide, a large ectodomain including N-glycosylation sites, an Aβ region, the Kunitz 
serine protease inhibitor domain, short cytoplasmic domain signaling the trafficking of 
APP, and a single membrane-spanning helix, copper and zinc binding domain as well as 
adhesion and neurotrophic domains (Mattson 1997; Selkoe 2001a). Its large cytoplasmic 
domain includes a consensus binding sequence (NPXY) where certain adaptor proteins 
become attached. YENPTY motif is a specific signal in the APP cytoplasmic tail, which 
usually exposes cell-surface APP for endocytic processes – mutations in this motif inhibit 
the internalization and thus decrease Aβ production (Perez et al. 1999).  
APP is involved in synapse growth, memory retention (Meziane et al. 1998), neuronal 
maturation (Hung et al. 1992), the differentiation of neural stem cells (NSC) into astrocytes 
(Kwak et al. 2006) and NSC proliferation in the subventricular zone (Caille et al. 2004). APP 
also colocalizes with integrins on the surface of axons and at sites of adhesion (Yamazaki et 
al. 1997) and it also has receptor-like functions, e.g. F-spondin may bind to APP and reduce 
its cleavage by β-secretase (Ho and Südhof 2004).  
Aβ is cleaved from the Aβ region of APP through sequential cleavages. Under normal 
conditions α-secretases cleave APP twelve amino acids outside from the membrane 
yielding extracellular aminoterminal ectodomain of APP (sAPPα) and a membrane bound 
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APP C-terminal fragment (83-residue CTF, C83) (Esch et al. 1990) (Fig. 1). This non-
amyloidogenic pathway occurs primarily at or near the cell surface (Vetrivel and 
Thinakaran 2006). In addition, other enzymes e.g. A Disintegrin and Metalloproteinase 
family (ADAM) enzymes or aspartyl protease BACE2 may cleave APP at the same site.  
In the amyloidogenic pathway, β-secretase (beta-site APP cleaving enzyme 1 = BACE1), 
occurring typically at the low pH present in endosomes, cleaves APP further from the 
membrane (Cole and Vassar 2007) and gives rise to smaller ectodomain derivatives (βAPPs) 
and longer 99-residue CTF, C99). In late-onset AD, oxidative stress may activate β-secretase 
and thus facilitate the secretion of Aβ (Reddy 2006). C99 can be further cleaved by γ-
secretase, which contains also the complex formed by presenilin, anterior pharynx 
defective-1, presenilin enhancer-2 and nicastrin (De Strooper 2003). The cleavage site at 
residues 712 or 714 produces either Aβ1-40 or Aβ1-42, respectively (Hardy 1997). See the 
illustration of the APP processing in Fig.1. 
 
 
 
Figure 1. The APP processing and formation of Aβ peptides (modified from Nixon 2007) 
Approximately 90 % of the secreted Aβ is Aβ1-40, the rest 10 % being Aβ1-42 (Selkoe and 
Wolfe 2007). Aβ1-42 is more prone to aggregation and fibril formation compared to Aβ1-40 
(Snyder et al. 1994) and it is more prominent in amyloid plaques (Younkin 1998). The more 
soluble Aβ1-40 is the form typically found in vascular deposits (Smith et al. 2009). APP is 
post-translationally modified (N- and O-glycosylation, ectodomain and cytoplasmic 
phosphorylation, tyrosine sulfation) during transit from the endoplasmic reticulum (ER) to 
the plasma membrane and after this the majority of APP is localized to the Golgi and Trans-
Golgi-network (TGN). Typically, Aβ is generated in neurons in several intracellular sites. β-
secretase cleaves APP in early Golgi, late Golgi/early endosomes and endosomes which 
have an acidic environment (Huse et al. 2002; Vassar et al. 1999) and γ-secretase in ER, 
Golgi-TGN, endosomes and plasma membrane (Cupers et al. 2001). When the disease 
progresses, the overproduction of Aβ in cellular compartments interferes with normal cell 
function (LaFerla et al. 2007). In non-neuronal cells, APP is endocytosed, delivered into 
endosomes, and finally either recycled to the cell surface or degraded within the lysosomes.   
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APP may cause AD through many different mutations principally affecting its 
proteolytic cleavage and specific APP mutations have been found from different families / 
populations. The mutation prior to the β-secretase cleavage site in APP gene 
(KM670/671NL) is a “Swedish mutation”, APPSwe and this increases the cleavage of β-
secretase and Aβ production (Mullan et al. 1992). Although the “Arctic” mutation (E693G) 
is located near the α-secretase site, this mutation increases proamyloidogenic β-secretase 
cleavage, thus increasing levels of Arctic Aβ (Sahlin et al. 2007). In the “London” mutation 
(V717I) the production of Aβ1-42 is increased due to a mutation at the carboxy-terminal of γ-
secretase cleavage site (Suzuki et al. 1994). The “Flemish” mutation (A692G; Kumar-Singh 
et al. 2002) and the Dutch mutation (E693Q; Van Broeckhoven et al. 1990) both inhibit the α-
secretase cleavage leading to the accumulation of Aβ in the vessel walls. To date, over 20 
different APP mutations have been found (Spires and Hyman 2005). 
2.1.4 Aβ aggregation and amyloid cascade hypothesis 
After APP is cleaved by secretases, the polymerization of Aβ monomers is possible, but the 
exact mechanism of polymerization is still unclear to some extent. Probably, Aβ 
paranuclear units self-associate in an end-on-end manner forming protofibrils and then 
they aggregate into fibrils and finally plaques (Roychaudhuri et al. 2009). It has also been 
suggested that oligomers are spherical aggregates, elongating later by collecting spherical 
subunits as a “string”. These protofibrils may be precurors for mature fibrils (Blackley et al. 
2000) or on the other hand, function as intermediates buffering Aβ monomer concentration 
(Goldsbury et al. 2005).  
Unspecified forms of higher order soluble Aβ oligomers have recently been postulated to 
be highly toxic (Walsh and Selkoe 2007), but the results from different studies are still 
rather conflicting, usually due to technical challenges (Rahimi et al. 2008). Many of the large 
(over 12-mers) synthetic oligomeric Aβ structures (Roychaudhuri et al. 2009) differ from the 
smaller dimers and trimers isolated from the brains of AD patiens – healthy individuals 
lack these oligomers (Townsend et al. 2006). For example Aβ oligomers and fibrils share 
beta structures and similar amounts of main chain hydrogen bonding providing resistance 
to exchange, but may differ in their reactivity to antibodies recognizing the generic epitopes 
of amyloids with different sequences (Kayed et al. 2003; O’Nuallain and Wetzel 2002).  
 Certain metals, for example Zn(II), Cu(II) and Fe(III) may induce precipitation and 
protease resistant accelerated aggregation of Aβ in vitro, even at low concentrations 
(Atwood et al. 2000; Bush et al. 1994a, b; Huang et al. 2004). These metals are part of the 
normal physiology, but in AD, their concentrations are significantly elevated in the 
neocortex and for example in amyloid plaques compared to healthy individuals (Lowell et 
al. 1998).  
The amyloid cascade hypothesis places Aβ peptides in the center of AD pathogenesis 
and proposes that AD is the result of increased production or decreased clearance of Aβ 
(Hardy and Higgins 1992; Hardy and Selkoe 2002; Selkoe 1991). Fig. 2 illustrates typical 
factors underlying the classical amyloid cascade hypothesis. In AD, it is hypothesized that 
APP processing is altered due to changes in cellular homeostasis or altered signal 
transduction. Genetic defects refer to alterations in APP or PS proteins. Excess processing of 
APP leads to overproduction of Aβ and neurotoxic Aβ deposition. The defective Aβ 
clearance may also induce the accumulation of Aβ deposits (chapters 2.3.3 and 2.3.4). In 
addition, environmental factors may contribute to the development of AD (chapter 2.1.1). 
In the final phase of the pathology there is a synaptic loss and defects in neurotransmitter 
function, resulting in the impairment of cognitive functions and dementia. A good example 
of the role of overexpressed APP can be found in chromosome 21 trisomy (Down’s 
syndrome) patients – triplication of the APP gene leads to the appearance of AD-like 
pathology in these individuals by their middle-age (Petronis 1999). 
 
7 
 
 
 
Figure 2. Classical working hypothesis based on the amyloid cascade (modified from Racchi and 
Govoni 2003).  
However, recent neuroimaging techniques have revealed several robust plaques in the 
brain parenchyma of cognitively normal individuals (Villemagne et al. 2008) and vice versa, 
some post mortem samples isolated from severely demented individuals exhibit no plaques 
(Terry et al. 1991). The intracellular accumulation of Aβ may partly explain the disease 
progression (Gouras et al. 2000; Knobloch et al. 2007; LaFerla et al. 2007) - diffuse Aβ 
deposits have been discovered also in astrocytes (Yamaguchi et al. 1998). In AD patients, 
intracellular Aβ precedes the appearance of extracellular Aβ deposits (Gouras et al. 2000). 
In AD mice, it has been shown that intracellular Aβ accumulates early in AD progression 
(Knobloch et al. 2007; Oakley et al. 2006). In addition, an increased Aβ1-42/40 ratio is believed 
to be inversely related with the age of AD onset, rather than earlier assumptions that it is 
related to elevated levels of toxic Aβ1-42 (Bentahir et al. 2006).  
2.1.5 Aβ and tau pathology 
The soluble tau protein normally promotes microtubule assembly and stabilization in 
neurons (Lee et al. 2001). In AD, tau becomes abnormally phosphorylated at certain 
residues, inhibiting its microtubule association. A large amount of unbound tau begins to 
form filamentous structures, but it is not completely understood how this misfolded tau 
induces cellular toxicity. One possibility is that hyperphosphorylated tau interferes with 
motor proteins and thus inhibits axonal transport before the formation of NFTs 
(Mandelkow et al. 2003).  
The Aβ deposits accumulate extracellularly and NFTs intracellularly, but Aβ probably 
can induce also tau pathology by altering many cell-dependent and independent 
mechanisms (LaFerla 2010). The link has been demonstrated in several ways e.g. by 
crossing mutant APP and mutant tau mice, which developed double transgenic mice with 
enhanced neurofibrillary pathology, compared to single mutant tau mice (Lewis et al. 2001). 
Furthermore, intracranial administration of Aβ into mutant tau mice triggered NFT 
formation within the amygdala (Götz et al. 2011). In addition, anti-Aβ antibody treatment 
of the triple transgenic AD mice expressing mutant APP, PS1 and tau initially reduced the 
level of intraneuronal Aβ and then early phospho-tau species through proteasomes (Oddo 
et al. 2004). Oligomeric Aβ may block the function of the proteasome and induce the 
development of tau-pathology (Tseng et al. 2008). Interestingly, in double transgenic mice 
(mutant PS1 / mutant tau), which do not overexpress human APP transgene and develop 
Aβ pathology (Oddo et al. 2008), tau pathology develops later and is less severe compared 
to the situation in triple transgenic AD mice overexpressing the APP gene. In addition, 
extracellular Aβ induces inflammatory cascades and alters brain cytokine levels, probably 
favoring the formation of tau pathology (Kitazawa et al. 2005). 
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2.1.6 Experimental models of Alzheimer’s disease  
The numerous animal models mimicking AD can roughly be divided into non-transgenic 
and transgenic models. Non-transgenic animal models are prepared by exposing the 
animals to agents causing neuronal loss and memory failure, e.g. kainic acid (Friedman et 
al. 1983) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA; Muir et al. 
1994) or by direct Aβ infusion into the brain (Craft et al. 2004). The Aβ infusion method 
provides information about the toxicity of different Aβ peptides, but it does not model the 
natural aggregation of Aβ in brain tissue. Several transgenic animal models have been 
created to drive expression of APP, PS or tau from a natural source and in that way to 
reflect better AD, but none of them shows complete AD specific pathological or behavioural 
abnormalities or extensive neuronal loss. Mice expressing as prominent AD 
neuropathology as possible and exhibiting early abnormalities in both behavioural and 
neuropathological features have been the most valuable tools e.g. for drug discovery 
purposes. The promoter used to drive the transgene expression plays an important role in 
this model.  
Borchelt et al. 1997 produced the double transgenic mouse model APP+PS1, where 
mutant PS1 (mutation: human PS1-A246E) overexpressing mice were crossed with mice 
harboring the APPSwe mutation. This was a marked improvement compared to single 
transgenic AD mouse models, since these animals developed AD pathology faster and 
produced Aβ deposits in hippocampus and cortex with associated gliosis. Cognitive 
impairment was observed at the age of 11-12 months and it correlated with the amount of 
total hippocampal Aβ (Puoliväli et al. 2002).  
APPSwe transgenic mice express a chimeric mouse/human (Mo/Hu) APP695 with 
mutations linked to familial AD (KM 593/594) (Borchelt et al. 1996; Savonenko et al. 2003). 
PS1 transgenic mice (line S-9) express human PS1 carrying the exon-9-deleted variant 
associated with FAD (PS1dE9) (Lee et al. 1997). The mating of these two genotypes creates a 
transgenic mouse APPSwe/PSdE9 (APdE9), which develops Aβ deposits more rapidly 
compared to other models, already at six months of age (Jankowsky et al. 2004; Savonenko 
et al. 2005). The mutant PS1 (PS1dE9) probably places a greater amount of APP β-CTF 
substrate in contact with γ-secretase, thus producing more Aβ1-42 but it does not alter the 
levels of Aβ1-40 (Jankowsky et al. 2004). The increase in the amyloid burden between 6 and 
18 months of age correlated well with deficits in episodic-like memory and also moderately 
impacts on the spatial reference memory while the levels of acetylcholinesterase, choline 
acetyltransferase in the hippocampus and cortex and somatostatin in the cortex were 
reduced only slightly (Savonenko et al. 2005). In particular, impairments in episodic 
memory were the first clinical signs of AD (Small et al. 2003).  
 
2.2 ASTROCYTES 
2.2.1 Origin and morphology  
All neural elements are derived from neuroepithelial cells, which form also the radial glia 
during the beginning of embryogenesis. Astrocytes are generated from three origins: 1) 
Radial glia (radial neuroglia) transforming from neuroepithelial cells in the embryonic 
ventricular zone (VZ) are progenitors of neurons and astrocytes during development 
(Malatesta et al. 2000; Noctor et al. 2001). Radial glia can transform into star-shaped 
astrocytes (Schmechel and Rakic 1979) or into specialized astrocytes, e.g. Bergmann glia 
(Racik 2003). In the neonatal caudal subventricular zone (cSVZ), radial glia-like progenitors 
may be transformed also into 2) glial intermediate progenitors. The cSVZ is located in the 
lateral ventricle and it forms a lining in the superficial layer of the hippocampus from CA1 
to CA3 area – these glial cells give rise to white matter astrocytes and oligodendrocytes 
(Levison et al. 1999). 3) Glial restricted precursors generate directly from neuroepithelial 
cells, bypassing the radial glial stage, developing into bipotential glial progenitors and 
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astrocyte-restricted progenitors (Cai et al. 2007; Liu and Rao 2004). Further, embryonic 
radial glia and intermediate progenitors give rise to gray matter (“protoplasmic”) 
astrocytes and neonatal SVZ progenitors generate white matter (“fibrous”) astrocytes. The 
tissue environment with its different levels of growth factors for glial progenitors regulates 
the gene expression of the very complex lines of astrocytes (Cai et al. 2007). For example, in 
the absence of transcription factor Olig2, the astrocytes develop into white matter 
astrocytes, whereas up-regulation of glial fibrillary acidic protein (GFAP) produces grey 
matter astrocytes. GFAP is a major component of astrocytic intermediate filaments called 
glial fibrils. The mixed composition of astrocyte lines in the same brain region are 
generated according the functional requirements of the environment.  
Due to the variations in their origins, the morphology of the astrocytes is very complex 
and heterogenic. In general, white matter astrocytes have thin, unbranched processes 
covering partly the nodes of Ranvier. Extensively branching grey matter astrocytes 
envelope synapses and partly form the neurovascular unit, by covering and metabolically 
connecting blood vessels to brain parenchyma (Nedergaard et al. 2003).  It is also important 
to note that there are several differences between human and rodent astrocytes. Human 
protoplasmic and fibrous astrocytes are larger (2-3 x) compared to their rodent 
counterparts, they have approximately 10 x more primary processes and one human 
protoplasmic astrocyte covers and may be responsible for integrating ~2 x 106 synapses, 
whereas a rodent astrocyte may only be involved with ~2 x 104 to 1.2 x 105 synapses 
(Oberheim et al. 2009).  
2.2.2 Physiological functions  
Astrocytes perform surprisingly many functions in the brain. Astrocytes support the brain 
structure and homeostasis, influence neuronal survival and differentiation through their 
ability to release several growth factors (e.g. neuronal growth factor, ciliary neurotrophic 
factor, brain derived neurotrophic factor, insulin-like growth factor-1, acidic and basic 
fibroblast growth factor), they take up and recycle the neurotransmitter glutamate and form 
and participate in the maintenance of the BBB. Astrocytes are also known to be actively 
involved in the inflammatory responses of the brain (Farina et al. 2007).   
During stress and injury, astrocytes proliferate, secrete many active agents e.g. 
proinflammatory cytokines which are present in many inflammatory conditions and they 
also express GFAP (Chen and Swanson 2003; Moynagh 2005). On the other hand, astrocytes 
also perform anti-inflammatory functions and can protect neurons from cell death e.g. 
cytotoxic effects induced by hydrogen peroxide (H2O2) and NO (Tanaka et al. 1999). 
Astrocytes can express high amounts of important antioxidants (e.g. ascorbic acid and 
glutathione) and antioxidant enzymes (e.g. superoxide dismutase, catalase, glutathione 
reductase and –peroxidase) (Dringen et al. 2000; Peuchen et al. 1997; Wilson 1997) and 
provide glutathione precursors for their neighboring neurons (Dringen et al. 2000). 
Astrocytes have an important role also in long-term potentiation (LTP), which ultimately 
forms the basis for learning and memory through plastic, constantly changing events in the 
brain. During LTP, neuronal circuits are activated at high levels and structural synaptic 
rearrangements take place (Stevens and Sullivan 1998). For example, glutamate, nitric 
oxide, arachidonic acid, certain neurotrophins and cell adhesion molecules have been all 
proposed as potential molecules involved in the learning process (Fitzsimonds and Poo 
1998). During the rearrangements in the synaptic contacts, the astrocytes surrounding the 
soma and dendrites may retract and provide more space on the membrane surface of 
certain neurons for new synaptic contacts (Theodosis et al. 1998).  
Glial cells express a wide variety of neurotransmitter receptors similar to neurons 
(Verkhratsky and Steinhäuser 2000). Most astroglia express receptors for purines and 
glutamate, but the overall expression of neurotransmitter receptors varies according to the 
specific brain region (Verkhratsky and Kirchhoff 2007a, 2007b, Verkhratsky et al. 2009). 
Astroglia can regulate the activation of N-methyl-D-aspartate receptors (NMDARs) 
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through Ca2+-dependent release of the NMDAR coagonist D-serine (Panatier et al. 2006) – 
an event which critically affects the formation of LTP.  
Gap junctions are formed by intercellular channels called connexons, which join the 
astrocytes as physically continuous structures (Giaume and Venance 1998). Due to the lack 
of electrical excitability and their inability to propagate an action potential, astrocytes 
utilize their endoplasmic reticulum (ER) for intra- and intercellular signaling. Special 
calcium pumps [sarcoendoplasmic reticulum ATPases (SERCAs)] transport Ca2+ into the ER 
lumen (Wuytack et al. 2002), where the Ca2+ concentration is very high (0.5 - 1 mM) 
compared to cytosol (Solovyova et al. 2002). Calcium is released through Ca2+ -gated Ca2+ 
channels [ryanodine receptors RyRs and inositol 1,4,5-trisphophate (InsP3)-gated receptors], 
which are sensitive to cytosolic Ca2+ levels (Bezprozvanny 2005; Hamilton 2005). The InsP3-
receptors are especially important for Ca2+ signalling in astrocytes (Deitmer et al. 1998). 
During Ca2+ waves, gliotransmitters including glutamate, ATP, D-serine, GABA and taurine 
mediate glial-neuronal and interglial signalling.  
Gap junctions connect astrocytes to each other, simultaneously allowing the passage of 
several molecules and balancing their intracellular concentrations (Rose and Ransom 1997). 
Astrocytes also communicate chemically or electrically with presynaptic neurons through 
gap junctions (Perea and Araque 2005). Some proportion of the neurotransmitters may 
diffuse out of the synaptic cleft during intense neuronal activity and this can increase the 
intracellular Ca2+ concentration inside the astrocytes. These calcium waves spread through 
the glial network, reactivating neurons and causing further neurotransmitter release. This 
integrated signaling between glial cells and neurons may partly evoke inflammatory 
responses. Increased synaptic transmission induces astroglial Ca2+ signaling through their 
perivascular processes, which trigger the release of vasoactive substances from the endfeet 
(Iadecola and Nedergaard 2007; Mulligan and MacVicar 2004). Gliotransmitters are 
released typically from astrocytes and pass also through the gap junctions, this being 
usually induced in response to Ca2+ signaling as described above (Halassa et al. 2006). These 
transmitters facilitate the communication between several cell types in the brain; the major 
gliotransmitters are the neurotransmitter glutamate as well as ATP and D-serine. 
In addition, extracellular ion homeostasis is maintained by astrocytes. More specifically, 
astroglia take up local excessive K+ ions through inwardly rectifying K+ channels and this 
allows spatial K+ buffering (Kofuji and Newman 2004). K+ is redistributed through the glial 
network and is coupled to astroglial water transport / redistribution through water channel 
aquaporins (Simard and Nedergaard 2004). Since the extracellular K+ concentration 
increases after neural activity (K+ efflux from neurons), this depolarizes neuronal 
membranes and alters their excitability (Kofuji and Newman 2004) and affects also the 
membrane voltages of astrocytes (Kelly and Van Essen 1974).   
Astrocytes are strongly connected to the glutamate-glutamine cycle. Presynaptic 
terminals release the excitatory neurotransmitter glutamate. About 20 % of glutamate 
released is accumulated into neurons (Verkhratsky and Kirchhoff 2007a) with the rest of the 
potentially toxic excess glutamate being taken up by astrocytes through two glutamate 
transporters i.e. excitatory amino-acid transporter 1 and -2 (EAAT1/GLAST and 
EAAT2/GLT-1) (Danbolt 2001). In Na+ pump/ATP consumption-cycle, one glutamate 
molecule together with 3 Na+ and 1 H+ ions are translocated in and coupled with the efflux 
of 1 K+ ion, and thus the transport of glutamate is electrogenic (Deitmer and Schneider 
2000). In astrocytes, ATP-dependent glutamine synthetase converts glutamate to glutamine 
(Norenberg and Martinez-Hernandez 1979). The nontoxic glutamine is recycled back into 
the extracellular space and taken up by neurons through uptake pumps, converted back to 
glutamate by phosphate-dependent glutaminase and stored into synaptic vesicles 
(Derouiche and Frotscher 1991; Yudkoff et al. 1989).  
However, instead of being converted to glutamine, glutamate may enter the TCA cycle 
to be converted to α-ketoglutarate (KG), or it can be synthesized into the inhibitory 
neurotransmitter gamma-aminobutyric acid, GABA (Magistretti and Pellerin 1999). The 
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loss of glutamate is compensated by astrocytes via the regulation of glutamine export 
(Magistretti and Pellerin 1999) or the neurons themselves are able to convert glutamate 
from glucose-originated pyruvate or astrocyte-originated lactate (Hassel and Brathe 2000a, 
b). In the glucose-lactate shuttle hypothesis, increased neuronal activity increases glutamate 
release, activating astroglial Na+ dependent glutamate transporters (Magistretti 2009). The 
Na+ concentration increases in astrocytes, stimulating glycolysis and lactate synthesis. 
Lactate (cotransported with H+) is further recycled to neurons through specific transporters, 
affecting also the pHe and pHi. However, astrocytes can control brain pH by other enzymes 
transporting H+ and HCO3-, these being connected with carbonic anhydrase activity 
(Kimelberg and Nedergaard 2010).  
The largest energy reserve in the brain is glycogen and this is located mainly in 
astrocytes – the synaptic activity and thus neuromitters regulate the glycogen levels 
(Magistretti et al. 1993). In particular, vasoactive peptide (VIP) and noradrenaline (NA) 
have been shown to regulate the short-term glycogenolysis and long-term glycogen 
resynthesis in astrocytes (Allaman et al. 2000).  
Astrocytes undertake several tasks in establishing the link between neuronal activity and 
local blood flow, i.e. they connect neurons, brain endothelium, pericytes and smooth 
muscle cells into a single functional entity (Iadecola and Nedergaard 2007; Zlokovic 2008) 
by controlling vasoconstriction and vasodilatation (Iadecola and Nedergaard 2007) and 
BBB function, transporting water and electrolytes as well as regulating energy metabolism 
through glucose utilization (Magistretti 2009; Simard and Nedergaard 2004; Zlokovic 2008). 
Astrocytes also secrete an important vasodilator, prostaglandin E2 (PGE2) (Zonta et al. 
2003). Figure 3 illustrates the main neuron-astrocyte interactions. 
 
Figure 3. Tripartite synapse and glial-neuronal-vascular unit. Astrocytes contact neurons and 
their pre-and postsynaptic terminals and wrap themselves around neighboring capillaries with 
their endfeet, thus creating “tripartite” synapses and glial-neuronal-vascular units. (1) 
Astrocytes link neuronal activity with the brain microcirculation by controlling vasoconstriction, 
vasodilatation and BBB. (2, 6) Astrocytes maintain neurotransmission by providing energy (e.g. 
circulation-derived glucose) and recycling the excess neurotoxic glutamate back into neurons in 
the nontoxic form of glutamine, but also maintaining the overall homeostasis in the brain (e.g. 
redistributing excess K+ ions through Kir-channels after neural activity, water transport). (3) 
Neurotransmission between pre- and postsynaptic neurons induces Ca2+ increase in astrocytes 
(“tripartite synapse”) and propagating Ca2+ waves through glial network. Neuronal signalling 
may also proceed to the astrocytes through 4) direct neuronal-glial synaptic contacts.  (5) 
Astrocytes communicate with each other (e.g. inducing Ca2+ waves) via gap junctions or 
through the release of gliotransmitters. Modified from Chvátal et al. 2008.  
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2.2.3 Astrocytes in neuroinflammation and Alzheimer’s disease pathology  
In AD and other neuropathological states, astrocytes undergo cellular swelling, 
hypertrophy-hyperplasia (astrogliosis) and proliferation (astrocytosis) (Delacourte 1990; 
Stoltzner et al. 2000). Astrocytes can be both beneficial and harmful during these 
pathological conditions. They produce the toxic mediators commonly found in various 
neurodegenerative diseases (Becher et al. 2000) but on the other hand, they support 
neurons using neuron-astrocyte interaction through gap junctions and by releasing 
neurotrophins (Blanc et al. 1998; Kirchhoff et al. 2001). Reactive astrocytosis causes 
significant astrocyte death (Eddleston and Mucke 1993) and in brain injury, dying 
astrocytes destroy neighboring cells (Lin et al. 1998). 
In the normal brain, GFAP and S100B expressions increase with aging (Hansen et al. 
1987; Sheng et al. 1996). S100B belongs to the S100 calcium binding protein family (Baudier 
et al. 1986) and is expressed only in a subtype of mature astrocytes enveloping blood 
vessels and by GFAP-immunonegative oligodendrocyte precursor cells (Hachem et al. 
2005). Since S100B is a neuroprotective protein, it promotes neurite growth (Bhattacharyya 
et al. 1992). It is overexpressed in the CSF early in AD (Peskind et al. 2001) and may induce 
the deposition of Aβ towards pathogenic forms (Mrak and Griffin 2001).  
When the acute neuroinflammation is converted into chronic stress, the glial response 
may become neurotoxic. Cytokine IL-1 induces the production of IL-6 and stimulates iNOS 
activity (Rossi and Bianchini 1996), whereas IL-6 induces astrogliosis (Selmaj et al. 1990) 
and activation of microglia (Heyser et al. 1997). IL-1 and IL-6 also induce overexpression of 
acute phase protein α1-antichymotrypsin (ACT) (Nilsson et al. 2001). Interestingly, ACT 
associates with Aβ (Abraham 2001) and its levels are increased in the grey matter of AD 
brains compared to controls (Pasternack et al. 1989). In AD, astrocytes can overexpress 
nitric oxide (NO) (Simic et al. 2000) and Aβ activates cultured astrocytes to produce IL-1β, 
NOS-mRNA and NO (Hu et al. 1998). In addition, Aβ also stimulates NF-κB-dependent 
pathway in microglia and monocytes that induces cytokine secretion (Combs et al. 2001).  
Extracellular ion homeostasis is extremely important for neuronal function. For example, 
the K+ homeostasis is maintained mainly by astrocytes through local K+ uptake and spatial 
K+ buffering (Kofuji and Newman 2004). During pathology, the extracellular K+ can rise 
over five-fold compared to normal, robust neuronal activity. If astrocytes become 
atrophied, their capacity to maintain ion homeostasis is impaired, thus affecting negatively 
to neurotransmission. 
Overall, it seems that inflammatory changes appear quite early in the AD brain. 
Inflammation related factors have been found in plasma from pre-symptomatic AD cases 
(Motta et al. 2007). In addition, focal glial cell activation was notably up-regulated before 
the amyloid plaque formation in 3 months old animal models of AD, suggesting that Aβ 
protofibrils may be one of the primary causes of glial activation (Heneka et al. 2005a). 
However, some recent studies have suggested that astrogliotic fields can be found also 
from areas without Aβ deposition in AD and non-AD individuals (Simpson et al. 2010) and 
that there is  no significant difference in GFAP expression between demented and non-
demented brains (Wharton et al. 2009).  
During the inflammatory response, activated astrocytes may form a glial scar 
(anisomorphic astrogliosis), which prevents the area of damage from spreading (Pekny and 
Nilsson 2005). Astrocytes may also react by post-insult remodeling and recovery of neural 
function (isomorphic astrogliosis). Glial scar formation may be beneficial since it produces 
neurotrophins for neuronal survival or harmful, inhibiting reinnervation (Sofroniew 2005). 
In general, the significance of astrogliosis in the aged non-demented or demented brain has 
remained an open question. According to Olabarria et al. 2010 using triple transgenic AD 
mice, astroglial degeneration / atrophy occurred during the early stages of AD pathology. 
Starting from the age of 6 months, astrocytes in the areas CA1 and dentate gyrus showed 
atrophic signs this becoming more significant at older age. Senile plaques appearing from 
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12 months onwards, triggered morphological astrogliosis only in the astrocytes associated 
with Aβ deposits, while the astrocytes further away from the deposits remained atrophic. 
Aβ deposits also often surround brain capillaries, impairing microcirculation (Bell and 
Zlokovic 2009). While astrocytes normally have several maintenance and regulating roles 
also in the microcirculation of the neurovascular unit, the damaged astrocytes in early AD 
are probably involved also in neurovascular unit dysfunction. It seems that partly as a 
result of the vascular Aβ deposits, the utilization of glucose is significantly reduced as is 
evident from the functional imaging studies (Mosconi et al. 2008). Several studies have 
shown that Aβ decreases the astroglial glucose utilization (Parpura-Gill et al. 1997). During 
glucose withdrawal, astrocytic glycogen is used in axons as lactate at least in white matter, 
thus AD also causes adaptations in the glycogen regulation in astrocytes (Wender et al. 
2000). 
However, inflammation may have also beneficial effects in the brain (Yan et al. 2003). 
Some of the cytokines secreted by astrocytes have anti-inflammatory effects (e.g. IL-10, 
TGF-β) and some of these are also elevated in AD (Grammas and Ovase 2001; Rota et al. 
2006).  
2.2.4 Degenerating astrocytes and defects in mitochondria induce neurodegeneration 
The atrophy of astrocytes is possibly a contributing factor in the pathogenesis of many 
neurodegenerative diseases, including AD. As previously stated (2.2.2.), astrocytes are 
critical for maintaining the homeostasis and microenvironment of the brain, and thus their 
degeneration is fatal for neurons. In AD, the normal function of astrocytes gradually 
deteriorates (2.2.3.) and ultimately these cells may undergo apoptosis. 
Several signals are involved in the induction of apoptosis in astrocytes. In general, one of 
the most important signals regulating apoptosis is the change in intracellular Ca2+ levels 
[Ca2+]i (McConkey and Orrenius 1997). The elevation of [Ca2+]i in CNS trauma and ischemia 
causes free radical generation and oxidative stress, mitochondrial dysfunction and caspase 
activation, leading to apoptosis (Lewén et al. 2000). Similarly to the situation in astrocytes, 
imbalanced regulation and reperfusion of Ca2+ and H2O2 exposure ultimately induces 
apoptosis, this being reflected in the translocation of NF-κB p65 subunit, DNA 
fragmentation and nuclear condensation (Takuma et al. 1999). In AD, Aβ peptides induce 
spontaneous [Ca2+]i signals and oscillations in astrocytes, further damaging neurons 
(Abramov et al. 2003, 2004).  
In addition to Aβ-induced Ca2+ reperfusion and the subsequent impairment of astrocyte 
function in mitochodria, mitochondrial oxidative stress occurs already before the onset of 
Aβ pathology (Devi et al. 2006). The abnormal mitochondria present in neurons and 
astrocytes in AD affected brain are more easily damaged by free radicals (Abramov et al. 
2004; Manczak et al. 2004). Cytochrome c activates procaspase 9 and the downstream 
caspases involved in apoptosis (Budihardjo et al. 1999), leading to the opening of the 
mitochondria permeability transition pore, resulting in the loss of the mitochondrial 
membrane potential followed by the release of cytochrome c and other proapoptotic 
proteins (Kroemer et al. 1998) from the mitochondrial intermembrane space, which is a 
critical event during apoptosis (Green and Reed 1998). In addition, certain proteases 
(calpains, cysteine proteases cathepsins B and D) are involved in astrocytic apoptosis 
(Shibata et al. 1998; Takuma et al. 2003). Superoxide radicals (O2•-) and H2O2 from the 
matrix and inner and outer membranes of mitochondria may be carried to the cytoplasm 
and eventually cause the oxidation of cytoplasmic proteins (Reddy 2006). In AD, reduced 
levels of mitochondrial enzymes involved in electron transport chain have been shown 
(Reddy 2007). This reduces the production ATP, which is normally used in synaptic 
terminals for neurotransmission. 
Aging is often associated with impaired mitochondrial respiratory function (increased 
defects in mtDNA) (Kujoth et al. 2006). The brain is more vulnerable to oxidative stress 
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because of its high lipid content and oxygen metabolism, and at the same time, because of 
its low anti-oxidant reserves (Reddy 2006).  
Table 1 the displays the most important physiological functions of astrocytes during 
either health or cellular dysfunction in AD pathology, based on the text in chapters 2.2.2.-
2.2.4. 
 
Table 1. The principal roles of astrocytes in health and AD pathology 
Normal Functions of Astrocytes Astrocytes in AD pathology 
Support the brain structure and homeostasis, 
maintain the BBB 
Astrogliosis, astrocytosis, apoptosis, glial scar 
formation 
Growth factors for neuronal survival and 
differentiation 
Secretion of neuronal growth factors decreased, 
secretion of toxic mediators increased 
Pro- and anti-inflammatory functions Overproduction of pro-inflammatory agents, 
propagation of inflammatory processes 
Antioxidant functions Mitochondrial dysfunction, reduction of glutathione, 
oxidative stress 
Extracellular ion homeostasis, K+ buffering Reduced ability to maintain ion homeostasis (e.g. 
atrophic astroglia, increased extracellular K+ 
concentration)  
Communication with neurons (gap junctions and 
Ca2+ waves) 
Altered calcium signaling (spontaneous Ca2+ 
oscillations) and defects in neuronal-glial 
communication 
Control of [H+]o Possible dysregulation of H
+ homeostasis 
Glutamate and GABA uptake Impairment of glutamate transporters (reduced 
expression, aberrant RNA synthesis, altered 
function) 
Control of cerebral blood flow Neurovascular unit dysfunction 
Water transport (aquaporin 4) Function during pathology unknown 
Energy reserve (glycogen) Decreased glucose usage, changes in glycogen 
regulation, decreased energy for 
neurotransmission 
Participation in long term potentiation (LTP) Defects in supporting LTP 
 
2.3 Aβ CLEARANCE AND TRANSPORT MECHANISMS 
2.3.1 Aβ clearance, transport and chaperones 
Since Aβ is a polar substance, it is not able to permeate through the BBB, and therefore the 
excess Aβ must be transported out of the brain in some other way. Brain interstitial fluid 
(ISF) bulk flow clears 10-15 % of Aβ out of the brain (Shibata et al. 2000), but also other 
transport systems exist. Soluble Aβ transport is regulated by receptor for advanced 
glycation end product (RAGE) (Deane et al. 2003) and the low-density lipoprotein receptor 
related protein-1 (LRP1) (Shibata et al. 2000, Deane et al. 2004). Two receptors, megalin 
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(Zlokovic et al. 1996), P-glycoprotein (Cirrito et al. 2005) as well as apolipoprotein E (apoE) 
and apoJ probably transport Aβ across the BBB (DeMattos et al. 2004; Zlocovic 2005). α2-
Macroglobulin (α2M) can promote the degradation of α2M-Aβ complexes by proteases 
(Lauer et al. 2001) or participate in Aβ clearance  through LRP-1 mediated endocytosis 
(Narita et al. 1997). Tissue-type plasminogen activator (tPA) affects plasminogen transfer 
into plasmin but also accelerates the Aβ clearance in AD mouse models (Kingston et al. 
1995; Melchor et al. 2003). Furthermore, Aβ degrading proteases (Iwata et al. 2001; Selkoe 
2001b) as well as the astrocytes present in the cells of the neurovascular capillary unit 
(Koistinaho et al. 2004; Wyss-Coray et al. 2003; Zlokovic 2005) regulate the brain Aβ levels. 
Fig. 4 illustrates the most important factors regulating Aβ transport and clearance. 
 
 
 
Figure 4. ApoE and Aβ interactions in the brain and the pathways regulating Aβ homeostasis. 
Astrocytes and microglia secrete ApoE into brain interstitial fluid (ISF), whereas 1) neurons 
produce Aβ through APP cleavage mainly by α- or β-and γ-secretases. Aβ can be secreted out of 
the neuron and bind to ApoE-containing high density lipoproteins (HDLs). This complex may be 
transported into the blood circulation through 2) LRP or LDLR through BBB or into astrocytes for 
degradation.  Soluble Aβ may also be transported from blood to brain via 3) receptor for 
advanced glycation end products (RAGE) or be transported in both directions through 4) 
megalin (LRP2). Aβ may be slowly transported from brain to blood also via the 5) ISF-CSF bulk 
flow. Aβ is (6) degraded either intracellularly or extracellularly in the CNS by proteases (e.g. 
NEP, IDE, plasmin, MMPs) mainly produced by astrocytes and microglia. Aβ may also 7) 
aggregate, forming oligomers and deposits. Transport proteins  9) apolipoprotein E (apoE), apoJ 
or α2-macroglobulin (α2M) bind to Aβ and affect Aβ homeostasis in multiple ways – its 
sequestration  in plasma, brain ISF and CSF, accumulation form of Aβ (soluble / fibrillar) and 
transport across the BBB and blood-CSF barrier (modified from Fagan et al. 2002 and Zlokovic 
2005).  
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The actin-regulatory protein, gelsolin, in plasma inhibits Aβ fibrillization and degrade 
the already fibrillized Aβ, for example from transgenic AD mouse models (Matsuoka et al. 
2003; Ray et al. 2000) but also protect neurons from the toxic effects of Aβ (Qiao et al. 2005).  
The heparan sulfate proteoglycan (HSPG) family belongs to the proteoglycan 
superfamily affecting physical support, cell adhesion, motility, proliferation, differentiation 
and tissue morphogenesis (Bernfield et al. 1999). They consist of sulfated polymers of 
repeating disaccharides and subdivide into the extracellular matrix proteins and cell 
surface proteins. HPSG can be detected from senile plaques, cerebral amyloid angiopathy 
and neurofibrillary tangles (Perry et al. 1991; Snow et al. 1990). Heparan sulfates disturb Aβ 
fibrillogenesis (Gervais et al. 2001) and possibly transform the toxic Aβ oligomers and 
protofibrils into more harmless aggregates (van Horssen et al. 1999) and inhibit 
complement activation in AD. 
Some of the proteins associated with diffuse and fibrillar Aβ have been shown to 
promote the pathology of AD. Complement protein C1q binds fibrillar Aβ and activates 
complement cascade (Chen et al. 1996), the complement system becomes overexpressed 
(Yasojima et al. 1999) and correspondingly the complement inhibitor is down-regulated 
(Veerhuis et al. 1998). In addition, the levels of serum amyloid P (SAP), inhibiting the 
proteolysis of Aβ fibrils in vitro, are elevated (McGeer et al. 2001). C1q and SAP may bind 
together to Aβ and induce human microglia activation in vitro further (Veerhuis et al. 2003). 
The expression of the serine protease inhibitor α1-antichymotrypsin (ACT) is increased in 
AD, inducing also Aβ fibrillogenesis (Licastro et al. 1998). This protein activates rat 
astrocytes (Hu and Van Eldik 1999) and modifies the gene expression in cultured human 
astrocytes (Baker et al. 2007). During the early stages of AD, ganglioside GM1 induces 
soluble Aβ fibrillogenesis in the lipid rafts (Kawarabayashi et al. 2004). 
The classic heat shock proteins correct the misfolded proteins (Gusev et al. 2002) and 
small Hsps prevent incorrect folding (Buchner 1996). In AD, small Hsps αB-crystallin and 
Hsp27 are up-regulated in astrocytes around senile plaques and NFTs (Renkawek et al. 
1994a, b; Shinohara et al. 1993) and Hsp 20, HspB2 and HspB8 colocalize with Aβ in senile 
plaques and cerebral amyloid angiopathy (Wilhelmus et al. 2006 a, b). For example, αB-
crystallin retains Aβ in its neurotoxic protofibrillar state (Stege et al. 1999). It is possible that 
in aged AD cells, the capacity of heat shock proteins to stop the accumulation of excess Aβ 
is decreased (Nardai et al. 2002).  
2.3.2 Cholesterol, apoE and astrocytes in Aβ catabolism 
The majority of the brain cholesterol is synthesized de novo locally and is located in the 
myelin membranes, and 20 % in neuron and glial plasma membranes (Dietschy and Turley 
2001). The esterificated and hydroxylated cholesterol in the ER is transferred to the Golgi 
complex (Soccio and Breslow 2004) containing constantly endocytosed lipid rafts (Simons 
and Ikonen 1997). Extremely high amounts of cholesterol and also perhaps amyloidogenic 
Aβ producing BACE1 are located in lipid rafts (Cordy et al. 2003), whereas non-
amyloidogenic α-cleavage occurs in the phospholipid-rich part of the plasma membrane 
(Ehehalt et al. 2003). Aβ may be released into the extracellular space or remain in the 
plasma membrane or lipid rafts (Soccio and Breslow 2004). If Aβ ends up in the 
extracellular space, it may bind many of the proteins described above. It may also become 
attached to the ganglioside GM1 in the cholesterol / sphingolipid-rich membrane 
microdomain, which is possibly one reason for aggregation of Aβ (Kakio et al. 2001).  Both 
APP expression and Aβ production change in response to cholesterol levels in the lipid 
rafts (Gibson Wood et al. 2003). 
The brain astrocytes (Pitas et al. 1987) and to some extent microglia (Uchihara et al. 1995) 
secrete apoE into the brain interstitial fluid (Fagan et al. 2002). ApoE is a protein that 
transports cholesterol and other lipids in the plasma and the CNS by binding to cell surface 
apoE receptors (Mahley 1988). In the CNS, apoE is transported together with an esterified 
cholesterol core in HDL-like particles to neurons (Fagan et al. 1999; LaDu et al. 1998).  
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The extracellular Aβ binding to ApoE regulates its aggregation and cellular uptake. 
ApoE-Aβ complexes can be endocytosed through mainly neuronally expressed LRP (LDL 
receptor-related protein) and glial expressed LDLR (Rapp et al. 2006; Rebeck et al. 1993), 
which are the principal apoE / lipoprotein metabolic receptors in the brain. LRP1 binds the 
Aβ-ApoE complex at the endothelial ablumen and then the complex is internalized and 
degraded in lysosomes or transported into plasma (Shibata et al. 2000; Zlokovic 2004), but it 
also mediates free Aβ transport through BBB (Deane et al. 2004). ApoE / lipoprotein 
particles secreted by astrocytes have a higher affinity for LDLR than LRP1 (Fryer et al. 
2005). After endocytosis, the cholesteryl esters and Aβ are recycled back to the ER (Soccio 
and Breslow 2004). The apoE assisted clearance of Aβ is illustrated in Fig. 4. 
Astrocytes secrete also ABCA1, which links apoE with cholesterol and HDL-like particles 
(Hirsch-Reinshagen et al. 2005). ABCA1 transports both phospholipids and any excess 
unesterified cholesterol to apoE (Soccio and Breslow 2004). A deficiency of ABCA1 leads to 
the formation of lipid-poor apoE, which inadequately binds to the LDLR and LRP receptors 
and thus inhibits the clearance of Aβ (Ruiz et al. 2005). In addition, soluble apoE is 
transformed into its insoluble form at an accelerated pace and this causes a decline in the 
soluble apoE levels (Hirsch-Reinshagen et al. 2005). The lipidation status of apoE effects its 
conformation (Fisher and Ryan 1999), intrinsic stability (Hirsch-Reinshagen et al. 2005) and 
interaction with membrane receptors (Ladu et al. 2006).  
The human ε4 allele of apoE is the strongest genetic risk factor for late-onset AD 
(Strittmatter et al. 1993), increasing the risk for AD by 3-15 fold and decreasing its time of 
onset. The lipid-rich apoE-HDL complex binds to Aβ in detergent-insoluble glycolipid rich 
membrane domains (DIGs) and affects its clearance through astrocytic LDLR or LDLR 
receptor-related protein (Koistinaho et al. 2004; Strittmatter et al. 1993), and thus its 
deficiency or the presence of varying alleles affect also the Aβ deposition and clearance 
(apoE2>E3>>E4) in AD mouse models (DeMattos et al. 2002; Holtzman et al. 1999). Single 
amino acid differences at positions 112 and 158 alter the protein structure and function, e.g. 
apoE4 binds preferentially to larger lipoprotein particles and possibly assumes a 
pathogenic, unstable state (Hatters et al. 2006). The apoE3/lipoprotein particles bind to Aβ 
with higher affinity than apoE4/lipoprotein and thus clear Aβ more efficiently (LaDu et al. 
1994). Aβ binding to apoE4 redirects its clearance from LRP1 to VLDLR, which internalizes 
Aβ-apoE4 complexes more slowly (Deane et al. 2008). The apoE/Aβ-complex may also bind 
to heparin sulfate proteoglycans (HSPG) and facilitate the migration of Aβ in the 
extracellular matrix of the brain and arterioles, possibly accounting for the development of 
cerebral amyloid angiopathy.  
However, rodent and human astrocytes possibly react differently to Aβ. The primary 
human astrocytes and microglia are able to bind and ingest synthetic Aβ1-42 in vitro (Nielsen 
et al. 2009). In one experiment, the oligomeric Aβ was internalized more easily than its 
dense, fibrillar form. Later it was found that ApoE and ApoJ reduced considerably the 
uptake of oligomeric Aβ, whereas these same amyloid-associated proteins had only a 
minimal effect on fibrillar Aβ uptake (Nielsen et al. 2010). Contrary results were obtained in 
studies with AD mouse models, where the effect of ApoE was significant for astrocytic Aβ 
degradation, both ex vivo (Koistinaho et al. 2004) and in vivo (DeMattos 2004).  
Surprisingly, apoE also has a role in the proteolytic degradation of Aβ, probably through 
the activation of liver-X-receptor (Jiang et al. 2008). The reduced expression of two of the 
most important Aβ-degrading proteases, neprilysin and insulin-degrading enzyme has 
been associated with the ε4 allele – recently it has been shown that especially apoE3 
promotes Aβ degradation by NEP and IDE, whereas apoE4 is less efficient (Fan et al. 2009; 
Jiang et al. 2008). Fig. 4 describes the interactions between apoE and Aβ and the main 
pathways maintaining Aβ homeostasis in the brain. 
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2.3.3 The specific role of adult mouse astrocytes in Aβ degradation ex vivo and in vivo 
In AD, it is hypothesized that Aβ enhances the inflammatory processes within the CNS, 
causes malfunction of the glial cells normally maintaining brain homeostasis and thus Aβ 
ultimately contributes to neuronal degeneration. However, before the gradually 
accumulating Aβ burden and the associated inflammatory state reach a critical threshold 
point, astrocytes are still able to exercise their functions as housekeeping cells. According to 
several studies from the field, one of these important tasks is the clearance and degradation 
of Aβ. Aβ1-42-positive material which originated from local degenerated dendrites and 
synapses has been found in endogenic astrocytes in the entorhinal cortex of AD patients 
(Nagele et al. 2003) - neuron-specific proteins e.g. α-7 nicotinic acetylcholine receptor and 
choline acetyltransferase colocalized with these Aβ burdened astrocytes (Nagele et al. 
2002). The amount of the phagocytosed Aβ1-42 material in astrocytes correlated positively 
with the extent of local AD pathology (Nagele et al. 2003). Furthermore, astrocytic 
processes are capable of fragmenting Aβ plaques in AD patients (Wegiel et al. 2000). Adult 
astrocytes migrate, identify and degrade Aβ deposits ex vivo (Koistinaho et al. 2004; Wyss-
Coray et al. 2003), whereas neonatal astrocytes are not able to degrade Aβ deposits in vitro 
(Wyss-Coray et al. 2003) or ex vivo (Koistinaho et al. 2004)  
The internalization of Aβ deposits from Aβ-burdened transgenic mouse brain tissue into 
adult astrocytes can be blocked by co-culturing the astrocytes with antibodies against ApoE 
or Aβ or the LDLR antagonist RAP (receptor associated protein) (Koistinaho et al. 2004). In 
the same study, it was shown that adult ApoE-/- astrocytes (deletion of the ApoE gene) were 
not able to respond to and internalize Aβ deposits at the same level as wild-type adult 
astrocytes. All these results indicated that ApoE and LDLR are important in Aβ 
degradation by adult astrocytes ex vivo. Aβ binds to ApoE extracellularly and this complex 
is recognized and internalized by the LDLR receptor. The Aβ internalization in astrocytes 
may take place also through scavenger receptors on the cell surface and this interaction 
may be disturbed by fucoidan and polyinosinic acid, two known ligands for scavenger 
receptors (Alarcón et al. 2005; Allaman et al. 2010; Wyss-Coray et al. 2003). Furthermore, 
formyl peptide receptor-like 1 (FPRL1) is a G-protein-coupled receptor involved in immune 
responses, but it also mediates the Aβ internalization by astrocytes (Brandenburg et al. 
2008; Migeotte et al. 2006). In addition, leucine-rich glioma inactivated protein 3 (LGI3) is a 
type I transmembrane receptor involved in Aβ internalization, colocalizing with Aβ at the 
plasma membrane and intracellularly in astrocytes (Kimura et al. 2007; Okabayashi and 
Kimura 2008).  
Based on the recent findings, astrocytes isolated from healthy mouse brains are capable 
of degrading Aβ in vitro and in vivo. However, AD or even simply chronic stress may 
induce astrocytes to express Aβ producing BACE1, turning astrocytes into Aβ producers in 
addition to neurons, which normally are believed to be the exclusive source of Aβ (Rossner 
et al. 2005). BACE1 has been observed from activated astrocytes near Aβ deposits in AD 
mouse models (Tg2576 and double mutated K670N-M671L APP) (Hartlage-Rübsamen et al. 
2003; Heneka et al. 2005a; Rossner et al. 2001). Martins et al. (2001) also observed increased 
expression of APP, apoE and PS1 in a model of chronic reactive astrogliosis in vivo (Harvey 
et al. 1997; Sykova et al. 1999), which was created by grafting foetal cortical tissue into the 
midbrain and cortex of neonatal host rats. When the levels of proteins mentioned in the two 
types of graft and normal host cortex were evaluated, it was found that there was increased 
expression of GFAP in grafted astrocytes and activation of microglia (Harvey et al. 1997; 
Sykova 1999).  
2.3.4 Aβ degrading proteases in astrocytes 
The protease and peptidase enzymes are involved in the catabolism of proteins and 
peptides. Overall, more than 2 % of the genome codes for proteases indicating the 
important role of proteolysis in human biology (Puente et al. 2005). There are at least 561 
proteases and homologs in the human degradome, subdivided into 186 metallo-, 178 serine-
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, 21 aspartic-, 148 cysteine- and 28 threonine proteases (Puente and Lopez-Otin 2004). In 
each of these groups, proteases differ in their substrate specificity. The most important 
linking factor in each family is the presence of a crucial catalytic amino acid residue in the 
active site of the enzyme (e.g. serine in serine protease family), which attacks the carbonyl 
carbon of the peptide bond to be cleaved.  In addition to proteolytic effects, proteases also 
perform various regulatory functions mediated through intracellular signaling pathways, 
caspase-like enzyme activity and / or regulation of specific cytokines and signaling 
receptors.  
The zinc metalloproteases are the most well known class of Aβ degrading proteases. 
These are divided further into vasopeptides, matrix metalloproteases (MMPs) and 
homologs of insulin degrading enzyme (IDE). Neprilysin (NEP), endothelin-converting 
enzymes 1 and -2 (ECE-1 and -2) and angiotensin-converting enzymes (ACE) are named as 
vasopeptides due to their ability to process vasoactive peptides, but they also hydrolyze 
numerous other substrates (Turner et al. 2001). The vasopeptides are type 2 integral 
membrane proteins with their active site directed into the extracellular and/or lumenal 
space (Turner et al. 2001) and thus they are ideally positioned to degrade any secreted Aβ 
(Turner and Nalivaeva 2006). NEP (Iwata et al. 2000; 2004) and ECE-1 and -2 (Eckman et al. 
2001) are proteases known to participate in Aβ degradation in experimental animal models. 
In addition, IDE (Kurochin and Goto 1994), plasmin (Tucker et al. 2000), MMP-2 and -9 
(Backstrom et al. 1996; Roher et al. 1994), ACE (Hu et al. 2001) and cathepsins B and D 
(McDermott and Gibson 1996; Mueller-Steiner et al. 2006) degrade Aβ at least in vitro. The 
expression of NEP, ACE-1 and ECE-2 has been identified in the brains of AD patients and 
transgenic AD mice (Dorfman et al. 2010; Eckman et al. 2001, 2006; Hu et al. 2001; Iwata et 
al. 2000, 2004; Kanemitsu et al. 2003; Palmer et al. 2009; Zou et al. 2007). In addition to Aβ 
degradation, zinc metalloproteases have an important role also in the prevention of 
harmful, amyloidogenic Aβ generation. The ADAMs family of zinc metalloproteinases 
function as APP α-secretases (chapter 2.1.3.), directing the formation of Aβ towards its non-
amyloidogenic form (Gough et al. 2011). 
NEP and IDE as the principal Aβ degrading proteases regulate physiologically brain Aβ 
levels (Iwata et al. 2000; Iwata et al. 2001; Kurochin and Goto 1994) and interestingly, their 
levels are reduced in the aged brain (Savaskan et al. 2001). NEP is reduced particularly in 
the molecular layers of dentate gyrus (Iwata et al. 2002) and this might be linked to the fact 
that neurons in this area are especially vulnerable to Aβ deposition in AD. Recently, NEP 
levels were found to be overexpressed in AD, but this was restricted in sporadic cases 
(Dorfman et al. 2010). Interestingly, NEP is oxidatively modified in the AD brain (Wang et 
al. 2003) and may be inactivated by ROS (Shinall et al. 2005). In neurons, NEP overlaps 
especially with presynaptic terminals where Aβ is mainly secreted (Iwata et al. 2004), but 
the enzyme is found to be overexpressed in dystrophic neurites and the soma of the GFAP-
immunoreactive astrocytes around Aβ1-40/42 plaques (Apelt et al. 2003; Dorfman et al. 2010). 
In 2000, Iwata et al. showed that selective NEP inhibitor thiorphan inhibited strongly the 
degradation of radiolabeled Aβ1-42 superfused into rat hippocampus and also showed later 
that targeted disruption of the NEP gene considerably increased the endogenous Aβ levels 
(~100 %) (Iwata et al. 2001).  
ACE is localized in the plasma membranes of astrocytes in the circumventricular organs 
(Chai et al. 1990) and primary human astrocyte cultures express functional ACE-1 (Wosik et 
al. 2007). Normally, ACE converts angiotensin I to the vasoconstrictor angiotensin II (Agt 
II), which regulates the pressor response, balance of body fluid and electrolytes, 
neurohumoral functions and behavior (Allen et al. 1998; Phillips et al. 1987; Saavedra et al. 
1992). ACE inhibitors are used as drugs acting on the renin-angiotensin system to treat 
hypertension and thus they may delay the cognitive decline resulting from high blood 
pressure in AD (Hajjar et al. 2008; Kehoe and Wilcock 2007). However, ACE itself has been 
suggested to contribute to Aβ degradation; an alternative option is that ACE inhibitors may 
induce the up-regulation of NEP (Takeda et al. 2008). ACE was originally shown to degrade 
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Aβ1-40 in vitro (Hu et al. 2001). In addition, ACE can promote the degradation of naturally 
secreted Aβ1-42 (Hemming and Selkoe 2005) and convert Aβ1-42 to less neurotoxic Aβ1-40 (Zou 
et al. 2007). The polymorphism of the gene encoding ACE (insertion (*I) / deletion (*D) 
polymorphism, with the form DCP*I) has been postulated to be involved in the 
development of AD (Alvarez et al. 1999; Kehoe et al. 1999). Recently, treatment with the 
ACE inhibitor, captopril, increased Aβ1-42 accumulation in the Tg2576 AD model mice (Zou 
et al. 2007). However, also controversial results have been obtained from the studies using 
genetic or chemical inactivation of ACE (Eckman et al. 2006; Hemming et al. 2007; Iwata et 
al. 2000). In contrast to NEP and IDE, ACE levels are increased in multiple areas in aging 
brain (Savaskan et al. 2001).  
ECE converts inactive “big endothelin” into the vasoactive peptide, endothelin-1 (Turner 
and Murphy 1996). ECEs also hydrolyze various bioactive peptides in vitro, e.g. bradykinin, 
neurotensin and substance P (Hoang and Turner 1997; Johnson et al. 1999). ECE-2 differs 
from the other isoforms of ECEs in having an acidic pH optimum (Emoto and Yanagisawa 
1994) and in localizing mainly in the trans-Golgi network (Khimji and Rockey 2010). Based 
on these facts, ECE-2 has been suggested to participate in the non-classical processing of 
regulatory peptides (Mzhavia et al. 2003). It has been shown that secreted ECE-2 can 
degrade Aβ and ECE-2 KO mice have elevated levels of Aβ1-40 and Aβ-1-42 in their brains 
(Eckman et al. 2006). In AD, ECE-2 gene is also strongly down-regulated when compared to 
other forms of dementia (Weeraratna et al. 2007). However, Palmer et al. 2009 reported that 
ECE-2 expression was significantly increased in the neocortex, hippocampal pyramidal 
neurons and certain astrocytes and microglia in human postmortem AD brain.  
MMPs share a similar zinc-biding motif (HEXXH) with vasoactive peptides, but differ in 
the respect that they are proteolytically processed from the latent proenzymes into their 
active form (Vartak and Gemeinhart 2007), show a low basal expression but are stimulated 
by pathological insults (e.g. Aβ) and degrade fibrillar Aβ more avidly than the 
vasopeptides (Miners et al. 2008). The expression of MMP-9 is increased in AD (Backstrom 
et al. 1992; Lorenzl et al. 2003). In 2003, Deb et al. demonstrated that Aβ could stimulate 
MMP-9 production in astrocytes. In aged APP/PS1 mice, astrocytes overexpressed MMP-2 
and MMP-9 in the vicinity of amyloid plaques – these proteases might be secreted in the 
astrocyte conditioned medium (ACM) as plain ACM degrade synthetic Aβ (Yin et al. 2006). 
Inhibitors for MMP-2 and MMP-9 and ACM from mmp-2 or mmp-9 knock-out (KO) mice 
inhibited the Aβ degradation. In the same KO mice, clear increases in the steady-state levels 
of Aβ were found in vivo when compared to wild-type controls. MMP-inhibitor GM 6001 
increased brain ISF Aβ levels and the elimination of half-life of Aβ in APPswe mice.  
Glutamate carboxypeptidase II (GCPII) is a peptidase involved in folate metabolism, 
prostate tumorigenesis; in the brain it is expressed by astrocytes and it modulates also 
excitatory neurotransmission by hydrolysing the neuropeptide, N-acetylaspartylglutamate, 
thus releasing glutamate (Berger et al. 1999). GCPII reduced the plaque size and its 
inhibitor increased the Aβ content in the brains of transgenic APdE9 mice (Kim et al. 2010). 
The catalytic domain is located in the extracellular portion of the protein, and thus it is 
believed that this protease most probably is able to degrade extracellular Aβ. The shorter 
cleavage products (Aβ1-14 and Aβ2-14) of GCPII are less prone to aggregation, and this 
protease reduces effectively soluble oligomers and fibrils during co-incubation, thus 
probably causing less cellular toxicity compared to other Aβ degrading peptidases. Overall, 
GCPII belongs to the group of carboxypeptidases from the metalloprotease family, cleaving 
various forms of amyloids efficiently and this is probably an advantage as compared to the 
endopeptidases (Mueller-Steiner et al. 2006). 
Plasmin, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) 
belong to the serine protease family. Plasmin is thought both to cleave the α-site of APP 
and to degrade the released Aβ peptides in neurons. Interestingly, plasmin levels are 
reduced in the APOE ε4-positive AD patients (Ledesma et al. 2000, 2003). tPA and uPA 
convert the inactive plasminogen into its active form, plasmin (Myöhänen and Vaheri 
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2004). Fibrillar Aβ stimulates and may directly bind tPA (Kranenburg et al. 2002; Van 
Nostrand and Porter 1999) and Lee et al. (2007) found high levels of tPA in the astrocytes 
associated with Aβ1-42 containing deposits in the AD mouse models. 
Many of the cysteine proteases have been linked to Aβ degradation in in vivo 
pharmacological studies (Frautschy et al. 1998), but recently, only cathepsin B (Cat B) has 
been shown to have a role in vivo (Mueller-Steiner et al. 2006). CatB is involved in the Aβ 
degrading endolysosomal protein degradation pathway (Mort and Buttle 1997). The active 
CatB is associated with Aβ deposits (Mueller-Steiner et al. 2006). 
However, a wide array of other, still unknown proteases may be involved in Aβ 
degradation. More studies will be needed to clarify and confirm the previous results about 
which enzymes are able to degrade oligomeric, fibrillar and diffuse Aβ and compact Aβ 
plaques, and also to define the species-specific differences and to examine whether the 
degradation occurs in in vivo conditions. Still, there exists a controversy regarding the 
cellular and subcellular localization of these proteases. There are conflicting reports on their 
expression and activity during pathological conditions. It is important to note that the 
proteases cleave Aβ at different sites and probably, they co-operate in regulating the total 
levels of Aβ. A summary of the cellular and subcellular localizations of the selected Aβ 
degrading proteases is listed in Table 2.  
 
 
Table 2. The class, cellular and subcellular localization in the CNS and Aβ degradation capacity 
of key proteases involved in Aβ catabolism.  
Protease 
name 
Abbreviation 
Protease 
class 
Cofactor 
Clan / 
Family 
EC number 
 
Cellular 
localization 
within the 
CNS 
Subcellular 
localization 
Form of 
Aβ 
degraded 
References 
Neprilysin 
NEP 
Metallo-
endopeptidase 
Zinc 
MA / M13 
3.4.24.11 
 
Neurons, 
astrocytes, 
microglia 
Cell 
membrane, 
Golgi/ER 
Monomeric, 
oligomeric, 
diffuse, 
early Aβ 
aggregates 
Kanemitsu et 
al. 2003; 
Dorfman et al. 
2010; Walsh 
et al. 2002 
Insulysin 
(Insulin 
degrading 
enzyme) 
IDE 
Metallo-
endopeptidase 
Zinc 
ME / M16 
3.4.24.56 
Microglia, 
neurons, 
astrocytes 
Cell 
membrane, 
Golgi/ER,  
Cytosol, 
Mitochondria, 
Endosomes 
Monomeric Malito et al. 
2008; Kuo et 
al. 1994; 
Dorfman et al. 
2010 
Endothelin 
converting 
enzyme 1 
ECE-1 
Metallo-
endopeptidase 
Zinc 
MA / M13 
3.4.24.71 
Endothelial 
cells, 
neurons, glia 
Cell 
membrane, 
Golgi/ER; 
vesicles in the 
constitutive 
and regulated 
pathways 
Monomeric Davenport and 
Kuc 2000; 
Turner and 
Murphy 1996 
Endothelin 
converting 
enzyme 2 
ECE-2 
Metallo-
endopeptidase 
Zinc 
MA / M13 
Not yet 
included in 
IUBMB 
recommenda
tions 
Endothelial 
cells, 
neurons, 
astrocytes, 
microglia 
Cell 
membrane, 
trans-Golgi 
network;  
vesicles in the 
constitutive 
pathway 
Monomeric Emoto and 
Yanagisawa 
1994; 
Davenport and 
Kuc 2000; 
Khimji and 
Rockey 2010;  
Palmer et al. 
2009; Eckman 
et al. 2006 
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Dipeptidyl 
dipeptidase A 
(Angiotensin 
converting 
enzyme) 
ACE 
Peptidyl-
dipeptidase 
Zinc 
MA / M2 
3.4.15.1 
Endothelial 
cells, 
astrocytes, 
neurons 
Cell 
membrane, 
perinuclear 
region 
Monomeric Hu et al. 
2001; 
Hemming and 
Selkoe 2005; 
Chai and 
Johnston 
1995; Lind et 
al. 1985; 
Song et al. 
1992; Barnes 
et al. 1992; 
Miners et al. 
2008 
Gelatinase A 
(Matrix 
metallo-
proteinase 2) 
MMP-2 
Metallo-
endopeptidase 
Zinc 
MA / M10 
3.4.24.24 
Neurons, 
glia, 
endothelial 
cells 
Cell 
membrane, 
Golgi/ER 
Monomeric, 
oligomeric, 
fibrillar 
Rosenberg 
2009; 
Backstrom et 
al. 1992; Yin 
et al. 2006; 
Deb et al. 
1999 
Gelatinase B 
(Matrix 
metallo-
proteinase 9) 
MMP-9 
Metallo-
endopeptidase 
Zinc 
MA / M10 
3.4.24.35 
Neurons, 
glia, 
endothelial 
cells, 
macrophage
s 
Cell 
membrane, 
Golgi/ER 
Monomeric, 
oligomeric, 
fibrillar 
Rosenberg 
2009; Yan et 
al. 2006; 
Backstrom et 
al. 1992, 
1996; Yin et 
al. 2006; 
Gottschall et 
al. 1995;  
Muir et al. 
2002 
Glutamate 
carboxy 
peptidase II 
GCPII 
Metallo-
carboxy-
peptidase 
Zinc 
MH / M28 
3.4.17.21 
Astrocytes Cell 
membrane 
Monomeric, 
oligomeric, 
fibrillar 
Berger et al. 
1999; Kim et 
al. 2010; 
Mueller-
Steiner 2006 
Plasmin Serine 
endopeptidase 
--- 
PA / S1 
3.4.21.7 
Neurons Cell 
membrane 
Monomeric, 
oligomeric, 
fibrillar 
Ledesma et al. 
2000, 2003; 
Tucker 2000; 
Lee et al. 
2007; Van 
Nostrand and 
Porter 1999 
Tissue 
plasminogen 
activator 
tPA 
Serine 
endopeptidase 
--- 
PA / S1 
3.4.21.68 
Microglia, 
astrocytes, 
neurons, 
endothelial 
cells 
Cell 
membrane 
Fibrillar Aβ 
activates 
tPA, which 
activates 
plasmin 
Lee et al. 
2007: 
Kingston et al. 
1995; Wnendt 
et al. 1997: 
Strickland et 
al. 1996; 
Lochner et al. 
2006 
Cathepsin B 
CatB 
Cysteine 
--- 
CA / C1 
3.4.22.1 
Microglia, 
neurons, 
astrocytes 
Early 
endosomes, 
Lysosome 
Monomeric, 
oligomeric, 
fibrillar, 
diffuse 
Mueller-
Steiner 2006; 
Petanceska et 
al. 1994 
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2.4 MICROGLIA 
2.4.1 Origin and function 
Bone marrow gives rise to blood derived monocytes, which during embryonic stages 
migrate into the brain and maturate into microglia (Cuadros and Navascues 1998). The 
microglia present in the CNS are constantly renewed from BM-derived monocytes (Simard 
and Revest 2004.) Microglia represent about 5 % of the glial cells in the CNS (Pelvig et al. 
2008). Microglia function as immune effector cells in the CNS and belong to the 
mononuclear phagocytic system (McGeer and McGeer 1999). Resting microglia have a 
ramified surveillant-like morphology and in this state, they do not act as antigen presenting 
cells (APCs) and only weakly express MHCII molecules or cytokines (Streit 2002).  
Instead, activated microglia are converted into hypertrophied cells with condensed and 
hyper-ramified processes (Davalos et al. 2005). The later microglial population increases 
following mitotic events (Graeber et al. 1988). Microglial activation may be triggered by 
several signals, e.g. high extracellular concentrations of K+ (Davalos et al. 2005), IL-6 (Klein 
et al. 1997), IL-1 and TNF-α (Kloss et al. 1997). If neuronal death and cellular debris are 
present, the microglia can be transformed into phagocytic macrophages (Streit et al. 1999). 
This is thought to be an irreversible event and after exhibiting phagocytic activity, these 
macrophages probably undergo apoptosis (Jones et al. 1997).  
Microglial cell surface antigen expression changes rapidly after activation. For example, 
there are elevated expressions of surface protein CD11b (Jensen et al. 1999), leucocyte 
common antigen CD45 or macrophage marker F4/80 (Perry et al. 1985; Sedgwick et al. 1991) 
in situations of reactive microgliosis. Activated microglia produce proinflammatory 
cytokines, e.g. IL-1β and TNF-α (Bartholdi and Schwab 1997; Lambertsen et al. 2002; Streit 
et al. 1998) but also release anti-inflammatory factors, for example neurotrophic 
transforming growth factor-β1 (TGF-β1) (Lehrmann et al. 1998). In addition, activated 
microglia express proteins typical for professional phagocytes and immune cells, e.g. 
complement components and their receptors, major histocompatibility complex (MHC) 
glycoproteins and scavenger receptors (McGeer and McGeer 1999). CD68 is a marker 
related to lysosomal glycoproteins expressed in phagocytic blood monocytes / tissue 
macrophages, localized into endosomal / lysosomal structures (Holness and Simmons 
1993). If the activity of microglia is excessive and long-lasting, it may cause 
neurodegeneration because of the constant secretion of neurotoxic proinflammatory 
cytokines, chemokines, reactive oxygen species and NO (Nakajima and Koshaka 2004). For 
example in AD, microglia increase further the secretion of macrophage inflammatory 
protein-1α (MIP-1α), monocyte chemoattractant peptide-1 (MCP-1) and growth factor 
macrophage colony stimulating factors (M-CSF) (Lue et al. 2001). They are also positive for 
CD11a-c (β2 integrin family members) and immunoglobulin Fcγ receptors (CD64) 
(Akiyama et al. 2000).  
2.4.2 Interplay with astrocytes 
Astrocyte maintain microglia in the resting state, but increase their activity especially 
during neuroinflammatory states. For example astrocytes secrete immune modulators CC 
chemokine 2 (CC2), CXC chemokine ligand 10 (CXCL10) and previously mentioned IL-6, 
IL-1β, IFN-γ and TGF-β (Apelt and Schliebs 2001; Dong and Benveniste 2001; Farina et al. 
2007; Mehlhorn et al. 2000) – from these, astrocyte secreted CCL2 and CXCL10 probably 
modulate the activity and migration of microglia (Tanuma et al. 2006). APP overexpressing 
mice lacking the CCR2-receptor (a counterpart for the astroglial CCL2-ligand) show 
reduced Aβ clearance (El Khoury et al. 2007), suggesting that astrocytes and microglia also 
cooperate in Aβ clearance. Microglia also express the receptor for astrocyte- and neuron 
produced fractalkine (CX3CL1), and CX3CR1-knockout mice show increased neuronal 
damage (Cardona et al. 2006), suggesting that these glial cells co-operatively can protect 
neurons from neurotoxicity. Astrocytic TGF-β and IL-1β increase microglial anti-
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inflammatory functions and promote Aβ clearance by microglia, whereas astrocytic IFN-γ 
and TNF-α increase microglial pro-inflammatory potential (Basu et al. 2002; Lemere et al. 
2007; Shaftel et al. 2007). Astrocytes may also signal the presence of neuronal dysfunction to 
the microglia, by producing microglial mitogen macrophage colony stimulating factor 
(Rogove et al. 2002).  
2.4.3 Role in Aβ degradation and AD  
Microglia can internalize Aβ by two different mechanisms, either through receptor-
mediated endocytosis or through macropinocytosis. 
The internalization of fibrillar Aβ proceeds by receptor-mediated endocytosis and 
receptor-mediated phagocytosis through Pattern Recognition Receptors on the surface, 
normally recognizing molecular patterns typical for pathogens (Koenigsknecht and 
Landreth 2004; Paresce et al. 1996). Microglia take up fibrillar Aβ into phagosomes and 
similarly to all the other forms of Aβ, this complex is degraded in the endosomal-lysosomal 
system. The complex of α6β1 integrin, CD47 and the B-class scavenger receptor CD36 
(Bamberger et al. 2003) mediates the Aβ uptake through receptor mediated nonclassical 
phagocytosis (Koenigsknecht and Landreth 2004). In addition, activated Toll-like receptors 
(Tahara et al. 2006) and formyl peptide receptor-like 1 (FPRL1) are involved in Aβ 
internalization (Brandenburg et al. 2008).  
Microglia can internalize soluble Aβ (sAβ) spontaneously from the extracellular milieu 
both in vitro and in vivo by constitutive, nonsaturable, fluid phase macropinocytosis, a 
process which is dependent on actin and tubulin dynamics, not on receptor-mediated 
endocytosis – and finally cytoskeletal vesicle structures filled with sAβ fuse with and are 
degraded within the endolysosomal compartments (Mandrekar et al. 2009). Astrocytes and 
neurons also internalize sAβ, but according to Mandrekar et al. (2009), the internalization 
capacity in vitro is greater in microglia compared to astrocytes. However, from the 
heterogenous populations of astrocytes, some were as effective as microglia in sAβ 
internalization, whereas some did not take up Aβ at all.  The same group excluded also the 
possibility of clathrin-mediated endocytosis of Aβ by microglia, because sAβ did not 
colocalize with transferrin, a protein which is normally taken up through receptor-
mediated, clathrin-coated endocytosis (Mandrekar et al. 2009). Furthermore, the 
LDLR/LRP-1-mediated sAβ internalization was excluded because inhibition of fAβ receptor 
components and LRP did not block the sAβ uptake. 
Even though microglia internalize Aβ deposits, they do not necessarily clear Aβ without 
extra stimuli as in vivo studies indicate (Bard et al. 2000; Wyss-Coray et al. 2001). Aβ 
deposits disappear from transgenic AD mouse models after active Aβ immunization or 
passive Aβ-antibody treatment (Morgan et al. 2005). These antibodies become attached to 
the plaques and possibly engage with microglial Fcγ-receptors, stimulating Aβ 
phagocytosis by microglia. Fibrillar Aβ may also interact with the complement system C1q 
or C3b (Lee and Landreth 2010; Rogers et al. 2002). LPS injections also induce microglia to 
reduce the Aβ burden in AD mice (Herber et al. 2007). Further, LPS/IFNγ-activated human 
microglia or human acute monocytic leukemia THP-1 cells phagocytosed human Aβ 
deposits to some extent ex vivo, the latter being possibly enhanced by co-cultured human 
astrocytes (Hashioka et al. 2008).  
Newly recruited bone marrow derived cells that assume a microglial-like phenotype 
recognize Aβ deposits in AD mouse models and eliminate Aβ (Malm et al. 2005; Simard et 
al. 2006). Peritoneal macrophages expressing apoE2 secrete greater levels of MMP-9 when 
compared to the apoE3 or -4 expressing macrophages and contrary to the results above, it 
has been proposed that the efficient degradation of soluble and insoluble Aβ ex vivo 
happens probably through LDL receptors (Zhao et al. 2009).  
As previously mentioned, astrocytes effectively internalize and degrade deposited Aβ ex 
vivo, without stimulation. However, the evidence of their role in Aβ degradation in vivo has 
hitherto remained incomplete.  
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2.5 THERAPEUTIC IMPLICATIONS 
2.5.1 AD biomarkers and symptomatic treatments 
The effectiveness of a therapy for any neurodegenerative disease depends to a great extent 
on the stage of the disease. It is often complicated but of extreme importance to devise 
biological markers capable of indicating the early stages of AD, and furthermore, to be able 
to differentiate AD from mild cognitive impairment (MCI) and other forms of dementia. 
Individuals suffering MCI show a mild impairement in memory but do not meet the 
diagnostic criteria for dementia or AD. However, these people are at increased risk of 
developing AD (Delrieu et al. 2011) and thus could more likely benefit from early phase 
treatment. At the moment, there is no clear definition for MCI diagnosis or a method for 
identifying MCI affected individuals whose symptoms will later progress to AD. This area 
is under active research.   
The best established biological markers for AD diagnosis are the analysis of Aβ1-42, total 
tau protein and phosphorylated tau (p-tau) from cerebrospinal fluid (CSF) (Feldman et al. 
2008; Frankfort et al. 2008; Marksteiner et al. 2007). Recently, potential new, sensitive and 
early-stage biomarkers were evaluated from CSF and blood (Spitzer et al. 2010). The results 
confirmed a reduced Aβ1-42/1-38 ratio, elevated levels of several Aβ peptide variants, elevated 
APP/Aβ, elevated 12 kDa sAPP and elevated GFAP in the CSF of patients with AD 
compared to controls. When the AD-like biomarker profile was compared with the control 
profile, the activity of β-site AβPP cleaving enzyme (BACE1) was increased and this 
elevation correlated with CSF levels of Aβ40, t-tau, p-tau but surprisingly, not with Aβ42 
(Mulder et al. 2010). Neuroimaging markers in preliminary clinical studies, such as those 
revealing atrophy of the medial temporal lobe may be used for AD diagnosis (Galluzzi et 
al. 2008).  
In the early stages of AD, some of the medical treatments do seem to be able to slow 
down the deterioration in the symptoms, but not progression of the disease (Massoud and 
Gauthier 2010). Pharmacological symptomatic treatments include e.g. vascular prevention 
with antihypertensive agents, cholinesterase inhibitors (donepezil, rivastigmine, 
galantamine) and N-methyl-D-aspartic acid (NMDA) non-competitive glutamate receptor 
antagonist (memantine). The pharmaceutical industry naturally has shown great interest in 
the development of disease-modifying treatments and currently, some with the greatest 
potential are undergoing clinical trials: α-secretase activators, BACE1 inhibitors, γ-secretase 
inhibitors, active and passive immunization against Aβ, inhibitors of tau phosphorylation 
and treatments targeting oxidative stress, neuroinflammation, cholesterol metabolism and 
the neuroendocrine pathways. The first treatments regarding the Aβ hypotheses have 
proceeded into clinical trials but all of them have failed in phase III studies (Karran et al. 
2011).  
2.5.2 Astrocyte manipulation as a potential therapeutic strategy 
Reactive astrocytes themselves are an interesting therapeutic target in several CNS 
disorders. Both astrocytes and microglia have a major role in neuroinflammation which is 
intimately involved in Alzheimer’s disease. Reactive astrocytes release pro- and anti-
inflammatory cytokines, neurotrophic factors, complement factors, chemokines and 
reactive oxygen species, which have both neuroprotective and neurotoxic effects.  
The signal transducer and activator of transcription 3 (STAT3) is an important upstream 
signaling molecule in the astrocytic inflammatory pathway, regulating various cytokines 
and growth factors. Its deletion evokes inflammation and tissue damage (Herrmann et al. 
2008; Okada et al. 2006). On the other hand, inhibition of the other regulatory key molecule, 
NF-κB, in the inflammatory pathway causes opposite results in several models of CNS 
disease or injury by limiting tissue injury and increasing neuronal survival (Brambilla et al. 
2009; Dvoriantchikova et al. 2009). Since these key molecules are involved in complex 
pathways, their careful manipulation might be one way to reduce hyperactivated reactions 
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or to promote beneficial functions in astrocytes. Yet another approach is increasing the 
activity of nuclear factor erythroid 2-related factor 2 (Nrf2), which is a transcription 
activator binding to antioxidant response elements (ARE) in the promoter regions of several 
antioxidant target genes (Vargas and Johnson 2009). Nrf2 is expressed also in astrocytes 
and its activation could be considered to increase the antioxidant potential of these cells. 
This may also enhance the production of glutathione precursors for neurons.  
In animal models of AD, non-steroidal anti-inflammatory drugs (NSAIDs) have reduced 
glial activation and Aβ levels and improved memory functions (Heneka et al. 2005b; Lim et 
al. 2001; Yan et al. 2003), but clinical trials in recent years have given rather controversial 
results (Breitner et al. 2009; Sonnen et al. 2010; Szekely et al. 2008; Varvel et al. 2009; Vlad et 
al. 2008). 
Increasing the glycogen reserve (Swanson and Choi 1993) in astrocytes can protect also 
neurons. During hypoglycemia, treatment with a glycogen phosphorylase inhibitor 
increased astrocytic glycogen levels and promoted glycogen mobilization, thus reducing 
neuronal death (Suh et al. 2007). In vitro gene therapy could potentially be one way to 
increase the expression of GLUT1 in astrocytes and monocarboxylate transporter 2 in 
neurons; this could be able to protect neurons against excitotoxicity by enhancing lactate 
shuttling between neurons and astrocytes (Bliss et al. 2004). 
The studies examining the enhancement of neuroprotective capacity of astrocytes have 
been traditionally conducted mainly in vitro, but recently new methods have been 
developed for direct and selective examination and modulation of astrocytes in vivo. Grafts 
of stem or progenitor cells maturing to adult astrocytes and genetically modified grafts of 
astrocytes, which are able to produce specific molecules are being investigated. If one could 
achieve long-term modulation of the already atrophic endogenous astrocytes it might be 
possible to induce the proliferation and differentiation of these cells, and possibly provide 
one novel treatment strategy for AD. Successful approaches have emerged, such as cell 
transplantation methods in several neurodegenerative diseases, such as ALS (Boucherie et 
al. 2009), Parkinson’s disease (Bahat-Stroomza et al. 2009) and Huntington’s disease (Giralt 
et al. 2010). In the latter study, genetically modified transplanted astrocytes expressing 
brain-derived neurotrophic factor (controlled by GFAP promoter) conferred increased 
neuroprotective effects compared to wild-type astrocytes. Cell transplantation as a therapy 
is not yet feasible today. Major concerns of any stem cell transplantation are the rejection of 
allogfrats and difficulties of obtaining patient's own cells for transplantation, and the 
invasiveness of direct transplantation into the brain and especially into the multiple brain 
regions that are involved in cognitive functions and affected in AD. Moreover, there is no 
information regarding astrocyte transplantation in humans yet and the subsequent reaction 
of microglia and even neurons in response to possible degeneration of transplanted 
astrocytes in humans is a major concern.   
The possibility to halt the propagating vicious cycle of pathological inflammation in AD 
brain is, at the very least, a complicated challenge. Since transplanted astrocytes gravitate to 
Aβ deposits in vivo, they might also function as vehicles for anti-inflammatory medicines or 
neurotrophic factors being targetted at the areas affected by AD.  
Ongoing research is already seeking the ways to use the Aβ degrading capacities of the 
enzymes produced by glial cells. Boosting the production of intracellular and secreted, 
specifically Aβ degrading proteases in transplanted or even in endogenous astrocytes may 
have therapeutic relevance in the future. It is mainly zinc metalloproteinases but also 
enzymes from other protease families which play an extremely important role in the 
regulation of Aβ formation via the nonamyloidogenic pathway and in the degradation of 
Aβ, and therefore the targeted up-regulation of the Aβ degrading enzymes in astrocytes 
and microglia may provide one potential novel therapeutic strategy for AD. 
Typically, the poor permeability of drugs through the BBB and the lack of specificity 
pose challenges for CNS drug development (Gabathuler 2010). In AD, two inflammatory 
inhibitors of glial cells, MW01-5-188WH and arundinc acid have shown neuroprotective 
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properties (Himeda et al. 2006; Mori et al. 2006; Ralay et al. 2006). Potential drugs for AD 
affecting several functions in astrocytes are under constant development, e.g. the above 
mentioned glutamate transmission and excitotoxicity, oxidative stress-related enzymes and 
scavengers, cytokine and growth factor signalling (e.g. NFκB), signal transducer and 
activation of transcriptase 3 (STAT3) signaling (Allaman et al. 2010), nucleotides and their 
receptors (ATP, purinoreceptors) (Ryu and Larnon 2008; Tota et al. 2011) and epigenetic 
regulators (Qureshi and Mehler 2011). Other astrocyte-specific molecules and regulators 
potential targets for drug development include the water channel protein aquaporin 4, 
connexin gap junctions (Cx43) and inwardly rectifying K+ channels (Kir) (Wilcock et al. 
2009). 
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3 AIMS OF THE STUDY 
Together with increased inflammation and activation of both astrocytes and microglia,  
massive aggregation of Aβ deposits in the brain parenchyma classically represent one of 
the most important hallmarks of Alzheimer’s disease. Recently, the role of astrocytes as Aβ 
phagocytosing glia cells has been demonstrated, but their exact mechanisms in Aβ 
internalization and degradation are still far from clear. The purpose of this thesis was to 
clarify the Aβ degradation mechanisms of astrocytes in order to shed light on potential 
novel drug targets for AD.  
 
The specific aims of this thesis were: 
 
1. Previously mouse astrocytes have been shown to degrade Aβ deposited in 
transgenic mouse brain sections. This study established a model for studying 
astrocyte functions in human AD tissues and examined if adult and neonatal mouse 
astrocytes would be able to degrade Aβ deposits ex vivo also from post-mortem 
human AD brain tissue samples.  
 
2. Despite the potential of mouse astrocytes to clear Aβ ex vivo, there was no previous 
evidence for a direct role of adult astrocytes as Aβ internalizing and clearing cells in 
vivo. This study examined if transplanted neonatal or adult mouse astrocytes could 
internalize the human Aβ deposits present in APdE9 mice in vivo and if so, what 
were the kinetics of astrocyte recognition, internalization and degradation of human 
Aβ. 
 
3. Theoretically, astrocytes may either internalize Aβ followed by intracellular 
degradation or secrete proteases that digest Aβ. This study clarified the role of Aβ 
degrading proteases in adult astrocytes both ex vivo and in vivo, but also explored the 
differences in the Aβ1-42 degrading proteases secreted by either neonatal or adult 
astrocytes ex vivo.  
 
4. Aβ clearance in vivo most likely occurs as an interplay between astrocytes and 
microglia. This study aimed at clarifying the cross talk between astrocytes and 
microglia by transplanting adult astrocytes and tracking the transplanted cells and 
endogenous astrocytes and microglia and examining their contribution to Aβ 
clearance and involvement in the neuroinflammatory response in AD mouse model.  
 
5. Neonatal and adult astrocytes are known to differentially respond to human Aβ. 
This study established an in vitro model for studying the responses of the different 
astrocytic populations at the genetic level and clarified which genes were up and 
down-regulated in Aβ degrading astrocytes using a whole genome array in order to 
better understand the signaling cascades involved in Aβ uptake and clearance by 
astrocytes.   
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4 MATERIALS AND METHODS 
4.1 ANIMALS 
All animal experiments were approved by the National Animal Experiment Board in the 
State Provincial Office of Southern Finland. The mice were housed under a 12-h light–dark 
cycle and allowed free access to standard rodent chow and water. The mice were group-
housed except after surgical operations when they were placed in individual cages. 
Astrocyte cultures were prepared from 6-8 weeks or 2-3 days old C57Bl/6J mice or 
transgenic mice expressing enhanced green fluorescence protein, eGFP (Okabe et al. 1997), 
purchased from Jackson Laboratories (Maine, USA) and maintained in C57Bl/6JJ strain in 
the Animal House of the University of Eastern Finland.  
Astrocyte transplantations were performed on APdE9 transgenic mice and their C57Bl/6J  
littermates (female, Study I, age: 22 months and Study II, age: 12 or 23-24 months) that were 
created by co-injection of chimeric mouse/human APPSwe and PS1-dE9 vectors, both 
controlled by their own mouse prion protein promoter element  (Jankowsky et al. 2004) and 
their wild-type C57Bl/6JJ littermates. The APdE9 mouse line undergoes fast Aβ 
accumulation with the first deposits appearing at approximately 4 months of age (Garcia-
Alloza et al. 2006). APdE9 mouse lines (Studies I-III, unpublished data) were provided by 
Prof. Heikki Tanila, A.I. Virtanen Institute for Molecular Sciences, University of Eastern 
Finland.  
Mouse brain sections used in the ex vivo assays (one mouse per study) were prepared 
from 23 months old female double transgenic mice expressing familial AD-linked APPSwe 
and PS1 A246E mutant genes (APP/PS1 mice, Borchelt et al. 1997) (Study I) and 16-21 
months old female APdE9 mice (Studies II, III, unpublished data). As control animals, 
C57Bl/6J littermates (Study I: 23 months and Studies II, III, unpublished data: 13-23 months) 
were used. In the ex vivo assay (Study I), AD human brain tissue was prepared from frontal 
cortical brain samples from an AD patient (74-year-old female, AD symptoms for 5 years 
with abundant AD neuropathology, 3 h postmortem delay), provided by Dr. Irina 
Alafuzoff, Department of Neuroscience and Neurology, Section of Neuropathology, 
University of Eastern Finland. 
The genotypes, ages, number, treatments and survival times of the mice used in Studies 
I-III and unpublished data are shown in Tables 3 (ex vivo studies) and 4 (in vivo studies). 
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Table 3: The species, genotypes and ages of brain sections used in different ex vivo studies 
described in the present thesis. 
 
Species, 
genotypes 
Age Purpose Study 
APP/PS1 mouse 23 months Brain sections for 
ex vivo Aβ 
degradation assay 
I 
C57BL/6J mouse 23 months Brain sections for 
ex vivo Aβ 
degradation assay 
I 
APdE9 mouse  16 months Brain sections for 
ex vivo Aβ 
degradation assay 
with protease 
inhibitors, ELISA 
II 
C57BL/6J mouse 13 months Brain sections for 
ex vivo Aβ 
degradation assay 
with protease 
inhibitors, ELISA 
II 
APdE9 mouse 21 months Brain sections for 
microarray study 
III 
C57BL/6J mouse 23 months Brain sections for 
microarray study 
III 
APdE9 mouse 19 months Brain sections for 
Aβ degradation 
assay with 
protease 
inhibitors, ELISA 
Unpublished data 
C57BL/6J mouse 18 months Brain sections for 
Aβ degradation 
assay with 
protease 
inhibitors, ELISA 
Unpublished data 
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Table 4: The genotypes, treatments, ages, survival times and numbers of mice used in in vivo 
experiments in the present thesis.  
Mouse 
genotype 
Infusion 
material 
Age 
(months) 
Survival 
time 
Number 
of mice 
used 
Study 
APdE9 Adult 
astrocytes 
22 1 day 2 I 
 
APdE9 Neonatal 
astrocytes 
22 1 day 2 I 
 
C57BL/6J Adult 
astrocytes 
22 1 day 1 I 
 
C57BL/6J Neonatal 
astrocytes 
22 1 day 1 I 
 
APdE9 Adult 
astrocytes 
22 3 days 3 I 
 
APdE9 Neonatal 
astrocytes 
22 3 days 3 I 
 
C57BL/6J Adult 
astrocytes 
22 3 days 1 I 
 
C57BL/6J Neonatal 
astrocytes 
22 3 days 1 I 
 
APdE9 Adult 
astrocytes 
22 7 days 2 I 
 
APdE9 Neonatal 
astrocytes 
22 7 days 2 I 
 
C57BL/6J Adult 
astrocytes 
22 7 days 2 I 
 
C57BL/6J Neonatal 
astrocytes 
22 7 days 1 I 
 
C57BL/6J Adult 
astrocytes 
12 8 weeks 18 II 
C57BL/6J PBS 12 8 weeks 16 II 
 
APdE9 Adult 
astrocytes 
12 8 weeks 15 II 
APdE9 PBS 12 8 weeks 12 II 
 
APdE9 Adult 
astrocytes 
23-24 2 weeks 2 II 
APdE9 Adult 
astrocytes 
23-24 4 weeks 2 II 
C57BL/6J Adult 
astrocytes 
23-24 8 weeks 5 II 
C57BL/6J PBS 23-24 8 weeks 6 II 
 
APdE9 Adult 
astrocytes 
23-24 8 weeks 8 II 
APdE9 PBS 23-24 8 weeks 8 II 
 
4.2 ASTROCYTE CULTURES (I-III, UNPUBLISHED DATA) 
Hippocampi and cortices were isolated from 6-8-week-old C57Bl/6J or eGFP mice (Studies 
I-III, unpublished data) and the tissue was suspended in Dulbecco’s Modified Eagle 
Medium DMEM/F12 (3:1, Gibco BRL, USA) containing 10 % heat-inactivated fetal bovine 
serum (Gibco BRL) and 100 U / ml penicillin-streptomycin (Gibco BRL), triturated 10 x and 
centrifuged at 1500 rpm for 5 min at RT. Then 0.25 % trypsin-EDTA (Gibco BRL) was added 
and the suspension was incubated at 37 °C for 30 min. Fresh culture medium was added 
and the suspension was centrifuged at 1500 rpm for 5 min. The cells were treated with 
Percoll (Sigma-Aldrich, USA), centrifuged at 1500 rpm for 10 min at RT or until the phases 
separated clearly and washed once with fresh culture media. The cells were plated onto 
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poly-L-lysine coated flasks in DMEM/F12 (3:1) containing 10 % heat-inactivated fetal 
bovine serum, 100 U / ml penicillin-streptomycin and G5 supplement (Gibco BRL) at a 
density of 4 x 104 cells / ml. To remove microglia, the glial cell cultures were shaken at 200 
rpm for 2 h before the experiments. In the studies with neonatal astrocyte cultures, 
hippocampi and cortices were isolated from 2 (I, II) and 3 (III) days old C57Bl/6J and eGFP 
mice according to the protocol described above with the exception that medium used was 
DMEM (+4,500 mg/L glucose, +L-glutamine, -pyruvate; Gibco BRL) without G5 supplement 
or Percoll treatment. 
4.3 THE PURITY ANALYSIS OF ASTROCYTE CULTURES (I, II, 
UNPUBLISHED DATA) 
Standard anti-GFAP (glial fibrillary acidic protein, 1:500; Dako Cytomation, Denmark) 
immunocytochemistry was used to determine the purity of astrocyte cultures in the 
suspensions used for transplantation experiments and ex vivo assay (I, II, unpublished 
data). The cell density for purity analyses was 2 x 104 cells/ well in 48-well plate. The cells 
were incubated with biotinylated goat anti-rabbit IgG (1:200 dilution; Vector Laboratories, 
USA) secondary antibody followed by Vectastain ABC Elite kit (Vector Laboratories) 
according to the manufacturer’s protocol. H2O2 and nickel-enhanced diaminobenzidine (Ni-
DAB) were added to detect the immunoreactivity. Three to four microscopic fields (800 µm 
x 800µm) per well and three to four wells per cell type were analyzed for the percentage of 
Ni-DAB stained cells of all cellular profiles in the field. Adult astrocyte cultures were 
determined to contain on average 99.8 % ± 0.4 % (Study I, Fig. 2B), 99.6 % ± 0.6 % (Study II) 
and anti-GFAP immunoreactive astrocytes, whereas the purity of neonatal astrocyte 
cultures was 99.1 % ± 1 % (Study I). Immunocytochemistry with microglial anti-Iba (ionized 
calcium-binding adapter molecule-1, 2 µg / ml Wako, Japan) and anti-CD11b (1:500 
dilution; Serotec, UK) antibodies detected less than 0.9 % of microglial cells in all 
experiments. 
4.4 ASTROCYTE TRANSPLANTATIONS (I, II) 
The 3rd-4th generation eGFP expressing adult (Studies I, II) and neonatal (Study I) astrocytes 
were trypsinized from the culture flasks. The cells were centrifuged at 1500 rpm for 5 min, 
resuspended into the culture medium and stored at 37 °C until used. Immediately prior to 
the intracerebral injections, the cells were resuspended in 0.1 M PBS for the final cell 
density of 50 000 cells / µl (Study I) and 62 500 cells / µl (Study II). APdE9 and wild-type 
mice at the age of 22 (Study I) or 12 / 23-24 (Study II) months were anesthetized 
intraperitoneally with Avertin (0.025 ml / g body weight) and immobilized in a sterotaxic 
apparatus (Kopf Instruments, USA). Temgesic® (5 µl / g body weight) was used as an 
analgesic. The astrocytes [1.0 x 105 (I) and 1.25 x 105 (II) cells / hippocampus] were injected 
bilaterally in 2 µl volume at a speed of 0.25 µl / min into the CA3 area of the hippocampal 
formation using the following coordinates: ± 0.3 cm medial-lateral (ML), ± 0.27 cm anterior-
posterior (AP), and -0.3 cm dorsal-ventral (DV) (Study I) and ± 0.31 cm ML, -0.27 cm AP 
and -0.28 cm DV (Study II). The injection needle was held still for 10 min before lifting it up 
slowly in 2 min. PBS injected APdE9 and wild-type mice were used as control groups. The 
wound was closed with sutures and the animals were monitored until they regained full 
consciousness. In Study II, APdE9 mice were transplanted with astrocytes at two different 
ages, 12 months when Aβ load is progressing rapidly and 23-24 months when the Aβ 
burden has already reached saturation. From the mice aged 23-24 months at the time of 
transplantation, two mice were sacrificed at the two weeks and two mice at the one month 
time points to follow the migration of transplanted astrocytes. The majority of the animals 
were allowed to survive for two months after transplantation in order to study the effects of 
exogenous astrocytes on the Aβ burden over the longer term. The genotypes, treatments 
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used, ages, survival times and numbers of the mice used in Studies I and II are described in 
Table 4. 
4.5 BRAIN PROCESSING AFTER TRANSPLANTATIONS (I, II) 
At time points of 1, 3 and 7 days (Study I) or 2 weeks / 1 month / 2 months (Study II) the 
mice were terminally anesthetized with Avertin® and perfused with heparinized saline 
(2500 IU / l) for two min. The brain was removed and post fixed by immersion in 4 % 
paraformaldehyde solution at 4 °C for 24 h followed by cryoprotection in 30 % sucrose at 4 
°C for 48 h. Finally, the brain was frozen in liquid nitrogen and stored at -70 °C until later 
use. Coronal 20-µm-thick sections were cut with a cryostat (Leica Microsystems GmbH, 
Germany) throughout the hippocampal formation, and the sections were stored at -20 °C in 
anti-freeze solution (0.05 M phosphate buffer / 30 % ethylene glycol / 15 % sucrose, pH 7.6) 
before immunohistochemical stainings. Fig. 5 shows the principle of the astrocyte 
transplantations accomplished in Studies I and II.  
 
 
Figure 5. The principle of the astrocyte transplantations used in Studies I and II. In Study I, 
adult or neonatal eGFP astrocytes were transplanted into the hippocampi of 22-month-old 
APdE9 or wild-type mice. At the time points of 1, 3 or 7 days, the mice were euthanized and the 
brains were dissected out and processed, followed by the Aβ immunohistochemistry and 
microscopy to observe the Aβ internalization capacity of the transplanted astrocytes. In Study 
II, adult eGFP astrocytes were transplanted into the 12 or 23-24-month old APdE9 or wild-type 
mouse brain. PBS injected APdE9 and wild-type mice were used as control groups in both 
studies. In Study II, the majority of the animals were allowed to survive for two months after 
transplantation (see the text). After brain processing, different immunohistochemical assays 
and quantitative analysis were accomplished in order to study the effects of exogenous 
astrocytes e.g. on the Aβ burden. 
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4.6 EX VIVO Aβ DEGRADATION ASSAY (I-III) 
APP/PS1 mice aged 23 months (Study I) and APdE9 mice aged 16 (Study II), 18 (Study III) 
or 19 (unpublished data) months, including their wild-type littermates (Table 3) were 
deeply anesthetized with Avertin® and perfused transcardially with ice-cold saline 
containing 2,500 IU / l heparin. The brains were dissected and frozen in liquid nitrogen. 
Sagittal sections were cut with a cryostat (Leica Microsystems GmbH) through the 
hippocampal formation at the thickness of 10 µm (Studies I, II, unpublished data) or 20 µm 
(Study III) and placed on top of glass coverslips coated with 1x poly-L-lysine. The sections 
were stored at -20 °C until use. The APdE9 or wild-type mouse brain sections on coverslips 
were placed on the bottom of the wells of 24- (Studies I, III) or 48-well (Studies II, 
unpublished data) plates. The C57Bl/6J or eGFP expressing astrocytes (adult or neonatal, 
3rd-4th generation) were seeded on top of the brain sections at a density of 4 x 105 (Studies I, 
III) or 2 x 105 cells / section (Studies II, unpublished data) in culture medium. After 24 h 
incubation, the medium was removed and the brain sections were fixed in 3.7 % 
formaldehyde with 0.1 M PBS for 20 min, rinsed with 0.1 M PBS and finally stored at 4 °C 
for later use in Aβ-pan immunohistochemistry. 
4.7 STUDIES WITH PROTEASE INHIBITORS (II, UNPUBLISHED DATA) 
Using the ex vivo assay in Study II, the effect of different protease inhibitors on the 
degradation of Aβ deposits by astrocytes was studied as follows. Neprilysin inhibitor 
(Tiorphan, 1 µM, Sigma, USA), ACE-1 inhibitor (Captopril, 1 µM, Sigma) or ECE-2 inhibitor 
(S3445, 100 µM, Sigma) were spiked into medium and coincubated with adult astrocytes on 
top of APdE9 brain sections (n = 8-10 sections per inhibitor). As control samples, adult 
astrocytes were added into the wells without protease inhibitors. After 24 h coincubation in 
37 °C, 5 % CO2, the medium was removed from the wells and the brain sections were 
processed for Aβ-pan immunohistochemistry. Fig. 6 shows the principle of the ex vivo assay 
with protease inhibitors. In order to determine the potential confounding effect of protease 
inhibitors on the viability of the cells, plain astrocytes were co-incubated with inhibitors at 
the designated concentrations in 24-well plates. After 24 h incubation, the cells were fixed, 
rinsed with PBS and stained with DAPI before visualization and cell counting in a 
fluorescence microscope (Olympus IX-71, Japan).  
 
  
 
Figure 6. The principle of the ex vivo assay used in Study II. 1) The adult astrocytes were 
incubated on top of the APdE9 brain sections burdened with human Aβ or additionally, with 
protease inhibitors (NEP/ACE-1/ECE-2). As a control, plain culture medium was incubated on 
top of the APdE9 section. 2) After incubation, the Aβ-pan immunohistochemistry was conducted 
on the brain sections. 
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In the in vitro degradation assay (unpublished data), a similar ex vivo assay as described 
above was first accomplished using adult or neonatal astrocytes incubated on top of the 
APdE9 or C57Bl/6J (wild-type) mouse brain sections (n=10-24). As controls, adult or 
neonatal astrocytes were incubated without brain sections or APdE9 or wild-type sections 
were incubated without astrocytes. After 24 h incubation, the plain medium (astrocyte 
conditioned medium, ACM) was collected from the wells, centrifuged at 12 000 rpm for 2 
min and stored at -70 °C.   
Next, these medium samples were pipetted into new 96-well plates. Medium isolated 
from incubations of adult or neonatal astrocytes and APdE9 sections was spiked with four 
different broad spectrum inhibitors at a concentration of 100 µM (n=6): Serine protease 
inhibitor (AEBSF, 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, Sigma), 
cysteine protease inhibitor (E-64, trans-epoxysuccinyl-l-leucylamido-(4-guanidino) butane, 
Sigma), metalloproteinase inhibitor (EDTA-Na2, ethylene diamine tetraacetic acid disodium 
salt) or aspartyl peptidase inhibitor (Pepstatin A, Sta, (3S,4S)-4-amino-3-hydroxy-6-
methylheptanoic acid, Sigma) in an attempt to silence the proteases present in the ACM.  
As controls, media collected from the wells without astrocytes (only medium and brain 
sections) and adult or neonatal astrocyte ACM incubated without brain sections were 
studied. In addition, adult and neonatal ACM without inhibitors added were investigated 
(n=6). Finally, 2 µg / ml of synthetic, oligomeric human Aβ1-42 (American Peptide, USA) was 
added into each well. After 24 h co-incubation at 37 °C, the medium was collected from the 
wells and the samples were analyzed using human Aβ1-42 ELISA according to the 
manufacturer’s instructions (Human β Amyloid 1-42 Colorimetric Immunoassay Kit, 
Invitrogen Corporation, USA). Fig. 7 shows the principle of this experiment. 
 
 
 
Figure 7. The principle of the ex vivo and in vitro assays (unpublished data). 1) Adult or 
neonatal astrocytes were incubated on top of the Aβ burdened APdE9 or wild-type brain 
sections. 2) After 24 h incubation, the medium was collected and 3) incubated further with 
broad spectrum protease inhibitors and Aβ1-42 or without inhibitors.  
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4.8 IMMUNOHISTOCHEMISTRY (I, II) 
In all of the immunohistochemical experiments, the brain sections were briefly air dried, 
encircled with ImmEdge Pen (Vector Laboratories) and rehydrated with 1 x PBS for 5 min. 
The endogenous peroxidase was blocked from the samples using an appropriate blocking 
solution for 20-30 min, followed by incubation with primary and secondary antibodies.  
Between the incubations, the samples were washed 3 x 5 min with 0.05 % Tween-20 in PBS 
(PBST). Finally, the samples were air dried for 15 min and mounted in fluorescence 
mounting medium with DAPI (4',6-diamidino-2-phenylindole, VectaShield, Vector 
Laboratories). In the double stainings, mounting medium without DAPI was used 
(VectaShield). 
4.8.1 Aβ-pan (I, II) 
Unconjugated rabbit polyclonal anti-pan β-amyloid (Biosource International, USA) 
recognizes the sequence of Aβ1–40 and related proteins in the region from amino acids 15–30. 
The blockers were 10 % normal goat serum (NGS, Chemicon International, USA) or 1 % 
BSA with 0.3 % Triton-X in PBST. Anti-pan β-amyloid was incubated at a 1:300 dilution in 5 
% NGS in PBST overnight at RT. Secondary antibodies Alexa 568 or 405-conjugated goat 
anti-rabbit IgG H+L (Invitrogen, USA, 1:200 dilution in 5 % NGS in PBST) or DyLight 405-
conjugated AffiniPure Donkey Anti-Rabbit (Jackson ImmunoResearch Laboratories Inc., 
USA, 1:200 dilution in 0.5 % BSA) were incubated for 1 h at RT.  
4.8.2 CD68 (II) 
CD 68 rat anti-mouse antibody (AbD Serotec, UK) detects surface macrosialin at low levels 
in resident mouse peritoneal macrophages. Macrosialin is a heavily glycosylated 
transmembrane protein e.g. specifically expressed by tissue macrophages and the murine 
homologue of the human macrophage glycoprotein CD68. Endogenous peroxidase was 
blocked with 0.3 % H2O2 in MeOH for 20 min, washed and incubated with 0.5 % PNB 
blocking reagent (Perkin Elmer) in PBS for 1 h at RT. The primary antibody, CD68 rat anti-
mouse (1:2000 dilution in PNB) monoclonal antibody was added on the sections, incubated 
overnight at RT (slow agitation) and washed. Secondary antibody (biotinylated goat anti-
rat, 1:200 dilution in PNB, Vector Laboratories) was added, the sections were incubated 1 h 
at RT, washed, incubated with SA-HRP (GE Healthcare Ltd, UK) diluted 1:100 in PNB for 
30 min and washed. The fluorophore, tyramide (amplification reagent from TSA-Plus 
Cyanine 3 system, Perkin Elmer, 1:100 dilution in amplification diluent), was incubated on 
the sections in the dark for 8 min.  
4.8.3 Aβ-pan & CD45 double staining (II) 
In order to visualize human Aβ together with microglial cells, Aβ-pan-
immunohistochemistry was conducted as described above, using Alexa Fluor 405 
conjugated goat anti-rabbit IgG (Invitrogen) as the secondary antibody. After incubation for 
1 h at RT, the sections were washed and endogenous peroxidase was blocked with PBS 
solution containing 0.1 % NaN3 for 30 min. The sections were washed and incubated in 
PNB (0.5 % blocking reagent in PBS) for 1 h at RT. After anti-Aβ pan 
immunohistochemistry, the anti-CD45 rat anti-mouse (AbD Serotec, 1:100 dilution in PNB) 
monoclonal antibody was added followed by an incubation overnight at RT. The CD45 rat 
anti-mouse antibody recognizes leucocyte common antigen CD45, which is a glycoprotein 
present on the cell surface of all nucleated hematopoietic cells and their precursors. After 
washing, biotin conjugated goat-anti-rat (Vector Laboratories, 1:200 dilution in PNB) 
secondary antibody was added. The sections were incubated 1 h at RT, washed, treated 
with SA-HRP-reagent (GE Healthcare Ltd, USA, 1:100 dilution in PNB) for 30 min and 
washed, followed by an incubation with the fluorophore tyramide. 
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4.8.4 Immunohistochemistry for Aβ degrading proteases (II) 
The immunoreactivities of NEP, ACE-1 and ECE-2 were determined from the APdE9 and 
wild-type mouse brains transplanted with astrocytes or injected with PBS, and also from 
the astrocytes used in the ex vivo assay to according the following double staining protocol. 
The brain sections with astrocytes on top were first fixed with 3.7 % formaldehyde for 20 
min and washed with PBS. The sections of the in vivo and ex vivo experiments were first 
blocked with 1 % BSA and 0.3 % Triton-X in PBS for 1 h.  
In the NEP immunohistochemistry experiments, mouse polyclonal anti-NEP goat IgG 
antibody (R&D Systems, USA) was added at 1.07 µg / ml working dilution in 0.5 % BSA 
and incubated overnight at RT. After washing, secondary antibody Red Alexa Fluor 
donkey anti-goat (Invitrogen) was added at 1:700 dilution, followed by 2 h incubation at 
RT. For ACE-1 immunohistochemistry, goat polyclonal anti-ACE-1 IgG, (Santa Cruz 
Biotechnology Inc., USA) was added at 2.85 µg / ml in 0.5 % BSA and incubated overnight 
at RT. After washing, secondary antibody incubation was performed as above. In the ECE-2 
immunohistochemistry tests, goat polyclonal anti-ECE-2 IgG (Santa Cruz Biotechnology 
Inc.) at 2.85 µg / ml in 0.5 % BSA was added and incubated overnight at RT. After washing, 
there was secondary antibody incubation as described above. 
Simultaneously with the primary antibodies described above (NEP, ACE-1 and ECE-2) 
Aβ-pan antibody (Biosource International) (working dilution 4.75 µg / ml in 0.5 % BSA) 
was added and incubated overnight at RT. After washing, DyLight 405 AffiniPure Donkey 
Anti-Rabbit secondary antibody (Jackson ImmunoResearch Laboratories Inc.) was added at 
a 1:200 dilution, followed by 2 h incubation at RT.  
In order to differentiate the signal arising from the section used in the ex vivo assay from 
that arising from cells plated on top, APdE9 and wild-type brain sections without added 
astrocytes were used as controls. The negative controls omitted primary antibodies.  
4.9 TUNEL (II) 
For TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) 
immunohistochemistry, ApopTag Red in situ apoptosis detection kit (Chemicon, USA) was 
used. The sections were air dried and encircled with ImmEdge Pen. The area within the 
rectangle was measured. The sections were rehydrated 5 min in PBS, permeabilized 5 min 
in precooled ethano-acetic acid mixture (absolute ethanol and glacial acetic acid 2:1) and 
washed. DNAse treatment was performed on a selected section as a positive control: DN 
Buffer (3 ml 1 M TRIS-base pH 7.2, 400 µl 1M MgCl2, 10 µl 1M DTT, add H2O 100 ml) was 
pipetted on the section and incubated for 5 min at RT. DNAse I (Sigma, stock 10 mg/ml) 
was diluted 1:1000 in DN Buffer. DN Buffer was removed and replaced with DNAse 
dilution, incubation 10 min at RT. DNAse was rinsed 5 x 3 min with H2O. The excessive 
liquid was removed and the samples were incubated in Equilibration Buffer (13 µl / cm2) 
for 5 min at RT. Buffer was removed and replaced with Working strength TdT enzyme (11 
µl / cm2, 70 % Reaction Buffer and 30 % TdT enzyme) and incubated 1 h at 37 °C (slow 
agitation). In the negative control, only Reaction Buffer was added. The reaction was 
stopped by washing the sections for 10 min at RT in Working strength stop / washing 
buffer (prepared by mixing 2 ml stop/wash buffer + 68 ml distilled H2O). The sections were 
washed and Working strength anti-digoxigenin conjugate (13 µl / cm2, prepared by mixing 
53 %  Blocking solution and 47 % Anti-Digoxigenin Conjugate) were added to the sections, 
incubated for 30 min at RT with slow agitation in the dark. The sections were washed 4 x 2 
in PBST and blocked 1 h with 10 % NGS in PBST. Rabbit polyclonal Iba1-antibody (WAKO, 
Japan) 1:250 dilution (conc. 2 µg / ml) in 5 % NGS in PBST was incubated O/N at RT on the 
sections. Iba1 is an actin-binding protein and a microglial marker that stains both resting 
and activated microglia (Ahmed et al. 2007) Alexa Fluor goat anti-rabbit 405 (Molecular 
Probes) was used (1:200 in 5 % NGS in PBST) as a secondary antibody. 
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4.9.1 Immunohistochemistry following TUNEL staining (II) 
Calcium ions are important signal mediators in all cells and associate with numerous 
calcium binding proteins, including Iba1. Iba1 is specifically expressed in activated 
macrophages/ microglia. The sections were washed in PBST 4 x 2 min, blocked with 10 % 
NGS in PBST for 1 h and incubated with rabbit polyclonal Iba1-antibody (WAKO, Japan) 
1:250 dilution in 5 % NGS in PBST overnight at RT. Alexa Fluor 405 goat anti-rabbit 
secondary antibody was incubated on the sections for 2 h at RT.  
 In addition, anti-GFAP immunohistochemistry was accomplished for the other 
half of the samples selected for TUNEL staining. Anti-GFAP labels astrocytes from the 
CNS, binding to the intermediate filaments of mature astrocytes. After TUNEL staining, the 
sections were washed in PBST 4 x 2 min, blocked with 10 % NGS in PBST for 30 min and 
incubated with rabbit polyclonal GFAP-antibody (DAKO, Denmark) 1:500 dilution in 5 % 
NGS in PBST overnight at RT. Alexa Fluor 405 goat anti-rabbit secondary antibody (1:150 
dilution) was incubated on the sections for 2 h at RT.  
 
4.10 ANALYSIS OF GENE EXPRESSION PROFILES (III) 
4.10.1 Separating the cultured astrocytes from top of the mouse brain section 
In study III, the possible differences in gene expression profiles in eGFP expressing 
neonatal and adult astrocytes ex vivo were examined. Isolated neonatal or adult astrocytes 
(4 x 105 cells / well) were cultured on top of 18 months old APdE9 or wild-type mouse brain 
sections (n = 6). Before the mRNA isolation process, the samples from two sections were 
pooled (n = 3).  
The plated astrocytes were incubated on top of the brain sections for 22 h, the medium 
was removed and the sections with cultured eGFP astrocytes were incubated with 1 x 
trypsin- ethylenediaminetetraacetic acid (EDTA) (500 µl / well) for up to 15 min at 37 °C. 
Trypsin treatment detached the astrocytes from the underlying brain section partially, but 
the cells did not lose their grip completely. The detachment was monitored in a standard 
light microscope. The trypsin was inactivated by removing the brain sections with 
astrocytes into a small Petri dish filled with FBS-containing culture medium. Under a 
fluorescence microscope (Olympus IX-71, Japan), the eGFP astrocytes were separated from 
the underlying brain section. A suction hose typically used for the microinjection 
techniques was modified for this purpose. One end of the tube contained a pipette tip as a 
mouthpiece and the other end a glass capillary stretched in a Bunsen burner. A 0.22 µm 
filter was added in the middle of the tube. The eGFP astrocytes were picked up gently from 
the underlying brain section using a wavelength of 468 nm in the fluorescence microscope 
and simultaneous light microscopy.  Two parallel samples were pooled into one 15 ml tube 
and centrifuged at 1500 rpm for 5 min. The supernatant was removed and the pellet was 
resuspended into 1 ml of culture medium. The cell suspension was removed into eppendorf 
tube and centrifuged again at 12 000 rpm for 3 min. 
 
4.10.2 mRNA isolation 
RibopureTM Kit (Ambion, Applied Biosystems, USA) was used for the total mRNA isolation. 
The cell pellet was lysed by triturating with 100 µl TRI reagent and incubating for 5 min at 
RT. Then, 40 µl chloroform was added and the samples were vortexed for 15 sec, incubated 
for 5 min at RT, centrifuged 12 000 x g 10 min at 4 °C and 100 µl was transferred to a new 
eppendorf tube. Subsequently, 50 µl ethanol was added and the tubes were vortexed. The 
samples were passed through a filter cartridge for 1 min at 12 000 x g and washed in 2 x 500 
µl Wash solution for 1 min at 12 000 x g. The filter was dried with 1 min at 12 000 x g 
centrifugation, 100 µl elution buffer was applied to the filter and the samples were 
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incubated for 2 min (RT). mRNA was eluted by 1 min 12 000 x g centrifugation and then 20 
µl of sample was mixed with 180 µl H2O and the absorbance was measured.  
4.10.3 Gene expression analyses 
The gene expression analysis was performed at Biomedicum Genomics (BMGen), 
University of Helsinki, Finland. After the mRNA quality control by Bioanalyzer / Nano 
RNA assessments, BMGen performed the gene expression analyses using 12 x Affymetrix 
GeneChip Mouse Genome 430 2.0 hybridizations (2-Cycle method) and the arrays were 
scanned with an Affymetrix GeneChip scanner. Microarray data was analysed with 
Genespring GX 11.0 (Agilent, USA). The raw data were preprocessed with the robust 
multichip algorithm (Irizarry et al. 2003), normalized per chip to the median and the 
differentially expressed data of all 12 microarrays containing 45101 probes were filtered by 
fold change > 2.0 or < 0.5. The altered gene expression in astrocytes was identified 
according to accompanying brain section (transgenic or wild-type; Study III, Fig. 1). The 
differentially expressed probe sets were statistically processed with Welch unpaired t-test 
assuming unequal variances (p < 0.05; fold change > 2.0 or < 0.5). Benjamini-Hochberg false-
discovery rate (FDR) correction for multiple testing was used to control the number of 
false-positives results. By using MS Excel, replicate probes for individual genes were 
combined by taking averages of values, excluding the probes without gene annotations. 
Differentially expressed genes were annotated to their molecular function and biological 
process using Gene Ontology (GO) annotations and visualization program Cytoscape 
(Shannon et al. 2003) and its plugin BiNGO 2.4.2 (p < 0.05, Benjamini-Hochberg FDR, whole 
GO annotation as reference set; Maere et al. 2005). Molecular function groups were 
categorized with CateGOrizer 3.2.18 (Hu et al. 2008) by making the classification with 
modified Generic GO_slim-list (http://www.geneontology.org /GO.slims.shtml). 
The expression profiles were compared to publicly available datasets (Cahoy et al. 2008) 
created by the same GeneChip Mouse Genome 430 2.0 Array (GEO accession: GSE9566), 
showing the expression profile of highly purified neurons, astrocytes and oligodendrocytes. 
The data regarding astrocytes included profiles from early postnatal age (1 d) up to later 
postnatal age (30 d) with morphologically fully differentiated astrocytes. One dataset was a 
mixed sample of mouse forebrain. The additional datasets were loaded as original CEL files 
and normalized with the same protocol as the present data. The combined datasets were 
clustered using the standard correlation coefficient. 
4.10.4 Quantitative Real-Time PCR 
Synthesis of complementary deoxyribonucleic acid (cDNA) was made by using 400 ng of 
total RNA, Maxima reverse transcriptase and random hexamer primers (Fermentas life 
sciences). The relative expression levels of mRNA encoding several genes were measured 
according to the manufacturer's protocol by quantitative RT-PCR (StepOnePlus™ Real-
Time PCR System; Applied Biosystems, USA) by using specific assays-on-demand (Applied 
Biosystems, USA) target mixes. The expression levels were normalized to Beta-2 
microglobulin (B2m) and presented as fold change in the expression ±SEM. 
4.11 MICROSCOPY AND QUANTITATIVE IMAGE ANALYSIS (I, II) 
In Study I, fluorescence microscope images were visualized in an Olympus AX-70 
(Olympus Corporation, Japan) and confocal microscope images were obtained with Nikon 
Eclipse TE300 equipped with Bio-Rad Radiance 2100 Laser Scanning System (Bio-Rad 
Laboratories, Hercules, USA) based on the expression of the fluorescent protein using 
appropriate filter sets. For the visualization of human Aβ and eGFP expressing astrocytes in 
the corresponding areas, 1-µm-thick confocal images were collected throughout the 
cryosection using Eclipse TE 300 (Nikon, Japan) equipped with the Radiance 2100 Laser-
Scanning confocal microscope system (Bio-Rad Laboratories). Adjacent thin sections were 
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analyzed for potential colocalization of human Aβ immunoreactive material (red) and 
eGFP signal (green) and internalization of Aβ by eGFP expressing astrocytes was visually 
confirmed if Aβ was found in the cytoplasm of the cell in several serial confocal images. 3D 
pictures and reconstructed surface images were generated with Imaris 4.1.3 software 
(Bitplane AG, Zürich, Switzerland). Colocalization analyses of confocal images were 
performed with Coloc module of Imaris software. Intensity thresholds were defined 
separately for both green and red channels and the same threshold values were used for all 
images analyzed. The area was defined as ‘‘colocalized’’ when the volume pixels (voxels) 
were above the set threshold in both channels. Due to limited migration of transplanted 
astrocytes, the colocalization analysis was performed for astrocytes that were found near to 
the injection site. Two to three fields per mouse containing eGFP expressing astrocytes 
within the hippocampi were randomly selected for the colocalization analysis.  
In Study II, the fluorescence microscope images from ex vivo and in vivo samples were 
acquired with an Olympus IX-71 inverted fluorescence microscope (Olympus Corporation) 
equipped with an Olympus DP 70 digital camera (Olympus Corporation) and DP Manager 
v2, 2.1.195 software (Olympus Corporation). For the visualization of human Aβ in Study II, 
eGFP-expressing adult mouse astrocytes and endogenous microglia in the corresponding 
areas, 0.3 µm thick confocal images were collected from in vivo experiments. The 
cryosections were scanned using Zeiss LSM510 META confocal microscope with LSM 5 
software (Carl Zeiss International, Germany). Fluorophores were excited with 405nm, 
488nm and 543nm laser lines and emissions were collected with 420-480nm, 500-550nm and 
LP560nm filters, respectively. The images were generated with LSM Image Browser (Carl 
Zeiss International). The acquisition of fluorescence and confocal images was performed in 
a single session, keeping the settings constant during the quantitation. 
Quantitative analysis was performed for sections of ex vivo and in vivo experiments 
(Study II). In the ex vivo experiments, the area occupied by Aβ immunoreactive material 
(Aβ burden %) was quantified from 8-10 parallel sections of 4-5 randomly selected fields / 
section, restricted to the hippocampal CA1,  CA2 areas and subiculum.  The quantification 
was performed using per area (%) method [ImagePro (Media Cybernetics, USA) or Image J 
1.43u (Wayne Rasband, NIH, USA) softwares] with both softwares producing essentially 
similar data.   
In the in vivo experiments (Study II), quantitative analysis was performed in the 
hippocampal area where most of the transplanted astrocytes were found. This area also 
contains a high amount of deposited human Aβ in the APdE9 mouse model used in the 
study.  Three to four parallel sections with 1-2 randomly selected fields / section were 
analyzed for each mouse. Analysis thresholds were kept constant through the analysis. The 
quantification was performed using the per area (%) method using both ImagePro and 
Image J 1.43u softwares in the quantification of the Aβ burden and the CD68 
immunoreactivity, with both softwares producing similar data. All the subsequent analyses 
were accomplished using Image J 1.43u software.  In addition, the JaCOP plugin (Bolte and 
Cordelieres 2006) of ImageJ 1.43u software was used in cell-specific colocalization analysis, 
when the percentage of signal A overlapping with signal B (and vice versa, expressed by 
Pearson’s and Mender’s coefficients) was being determined.   
4.12 STATISTICAL ANALYSIS 
The data were quantified with two tailed t-test (comparison between two groups, Studies I 
and II) or one-way ANOVA followed by Tukey’s post hoc test (Study I) or Tukey’s multiple 
comparison test (comparison between more than two groups, Studies II and unpublished 
data) using GraphPad Prism® version 3.02 (Study I) or version 4.03 (Study II) (GraphPad 
Software, USA). Significance was assumed if P < 0.05. 
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5 Results 
5.1 ADULT ASTROCYTES DEGRADE Aβ DEPOSITS IN HUMAN BRAIN 
SECTIONS EX VIVO  
Based on the recent results (Koistinaho et al. 2004; Wyss-Coray et al. 2003), adult astrocytes 
are able to degrade Aβ deposited in transgenic mouse brain sections. In Study I, a model 
was established to study Aβ clearance in human tissue. Adult astrocytes were co-incubated 
for 24 h with frontal cortical post mortem human AD brain sections and the possible Aβ 
degradation capacity of astrocytes was examined using Aβ pan immunohistochemistry. 
The quantification of the Aβ deposits revealed that adult astrocytes efficiently decreased 
human Aβ burden. The reduction in Aβ immunopositive deposits was on average 57 % 
compared with adjacent sections incubated with medium only (Study I, Fig. 1A). The adult 
astrocytes formed cavities inside the deposits of Aβ immunoreactive material (Study I, Fig. 
1C, D), whereas the corresponding area remained intact in adjacent control sections (Study 
I, Fig. 1B). Similar cavitation has been shown to occur also in the AD mouse brain sections 
when incubated with adult astrocytes (Koistinaho et al. 2004).   
In transplantation studies (Studies I and II), eGFP astrocytes were used, so that the 
transplanted cells would be distinguishable from the endogenous brain cells on the basis of 
their eGFP fluorescence. For the transplantation purposes, it was first confirmed using ex 
vivo assay that adult wild type and eGFP expressing astrocytes did not differ in their Aβ 
degrading capabilities (Study I, Fig. 2D-G). In addition, it was shown that adult astrocytes 
indeed degraded Aβ deposits i.e. it was not simply release of Aβ from sections into the 
medium which was happening. This was accomplished by collecting the culture medium 
after astrocyte co-incubation with brain sections and analyzing the presence of human Aβ1-
40 and Aβ1-42 in medium using ELISA (Study I, data not shown). In addition, eGFP 
expressing adult astrocytes formed typical multicellular aggregates ex vivo especially in Aβ-
rich hippocampal area (Study I, Fig. 2H), contrary to neonatal eGFP astrocytes (Study I, Fig. 
2I). This is in line with the previous results of Koistinaho et al. 2004, where the aggregation 
and networking ability typical for the adult astrocytes was postulated to be linked to their 
Aβ degrading capacity. 
5.2 ADULT ASTROCYTES TRANSPLANTED INTO APdE9 MOUSE BRAIN 
INDUCE Aβ DEGRADATION 
Previous experiments had demonstrated a notable human Aβ degrading capacity of adult 
astrocytes ex vivo. Study I continued as a short-term transplantation study, assessing the 
ability of transplanted adult and neonatal astrocytes to target and internalize human Aβ in 
APdE9 mice. The eGFP expressing astrocytes were transplanted into the hippocampal CA3 
area of female APdE9 mice and their wild-type littermates (C57Bl/6J, age 22 months). The 
mice were sacrificed after a 1, 3, or 7 day follow-up time. The transplantation did not affect 
the viability of adult or neonatal eGFP astrocytes, which expressed eGFP and migrated 
typically a few hundred micrometers (1.5 mm at a maximum) from the injection site to the 
surrounding tissue, remaining within the hippocampi at all time points examined. In the 
wild-type mouse, the pattern of migration was a thin string-like formation between the 
stratum radiatum and stratum laconosum moleculare or stratum laconosum moleculare 
and molecular layer of the dentate gyrus. In the APdE9 mouse, the transplanted astrocytes 
typically diverged from the path and associated with the adjacent human Aβ deposits. 
Confocal microscopy followed by reconstructed surface images and colocalization analysis 
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showed that eGFP, which is expressed in the cytoplasm of transplanted astrocytes, was 
present at the same physical location as the Aβ immunoreactivity. These data are the first 
evidence that transplanted adult astrocytes are able to internalize human Aβ in vivo. At the 
studied time points, an average of 44 % of the volume of transplanted adult astrocytes and 
19 % of that of neonatal astrocytes was filled up with Aβ immunoreactive material (Study I, 
Table 2). The extent of Aβ internalization by transplanted astrocytes 1, 3 or 7 days after 
transplantation is visualized in Study I, Figures 4 and 5. In conclusion, the results of Study I 
showed that adult and neonatal astrocytes are capable of finding, associating, and 
internalizing human Aβ from transgenic APdE9 mouse brain after a relatively short 
transplantation time. 
To assess the viability of adult astrocytes at later time points and to clarify the extent of 
their potential Aβ clearance under in vivo conditions, the time-points for transplantation in 
Study II were extended up to two months. In addition, the response of the endogenous 
microglia and astrocytes for the transplantated astrocytes was examined. At first, eGFP 
expressing adult mouse astrocytes or PBS were injected into the hippocampi of APdE9 mice 
and their wild-type littermates and the animals were sacrificed after the preterminated 
follow-up times. At all time points examined living, eGFP expressing astrocytes with 
typical ramified morphology were detected (Study II, Fig. 1). After a two-week follow-up 
time, the transplanted cells were typically found in large clusters or in string-like 
formations consisting of tens to hundreds of cells with the transplanted cells being located 
randomly in the vicinity of the human Aβ deposits, but were not specifically attracted by 
them. In some cases also single, dissociated cells were found. In the case that a cluster of 
astrocytes was found close to human Aβ, colocalization was usually detected. The 
maximum length of migration was only 0.5-0.6 mm (ML), 0.6-0.7 mm (AP) and 0.2-0.3 mm 
(DV) from the injection site, even at the two months time point. At the one-month follow-up 
time point, astrocytes were either in large clusters or dissociated from each other and were 
now more frequently colocalized with Aβ deposits (Study II, Fig. 1D-F, J). At the two-month 
follow-up time point, human Aβ was endocytosed by even more dissociated transplanted 
adult astrocytes since most of the Aβ immunoreactive material next to transplanted 
astrocytes colocalized with eGFP signal (Study II, Fig. 1G-I).   
In the area of numerous grafted astrocytes, the remaining Aβ deposits were smaller and 
Aβ immunoreactivity resembled that of thioflavin S-positive fibrillar plaques, appearing to 
be denser and brighter and thus it differed from the Aβ deposits in intact brain areas or in 
mice injected with PBS only. The quantification of Aβ immunoreactivity and analysis of all 
subsequent markers were restricted to the hippocampal area where most of the 
transplanted astrocytes were found. A significant, local Aβ reduction was discovered in 
APdE9 mice transplanted with astrocytes compared to APdE9 mice with PBS injection 
(Study II, Fig. 2). Importantly, the extent of Aβ reduction in the brain was found to be 
dependent on the timing of the transplantation in relation to the development of Aβ 
pathology. At the two-month follow-up time point, transplanted astrocytes had reduced 
the Aβ burden by 76 % (p < 0.0001) in 12-month-old mice compared to PBS injected APdE9 
mice (Study II, Fig. 2A). The APdE9 mice in this age exhibited an intermediate Aβ load with 
a substantial amount of diffuse Aβ deposits in the hippocampus (Savonenko et al. 2005). In 
the equivalent experiment conducted in APdE9 mice transplanted at the age of 23-24 
months the relative Aβ reduction was only 41 % (p < 0.05) as compared to the PBS injected 
APdE9 mice (Study II, Fig. 2B).  The transplanted astrocytes probably reduced the Aβ load 
more efficiently when Aβ pathology was still developing compared to the situation in an 
environment where the Aβ burden had already reached saturation and more mature and 
dense Aβ deposits were present.  
43 
 
 
5.3 TRANSPLANTED ASTROCYTES ACTIVATE MICROGLIA AND BECOME 
APOPTOTIC 
In Study II i.e. the transplantation experiments, the reduction of the Aβ burden after the 
transplantation of adut astrocytes was notably more extensive in the cohort of 12-month-
old APdE9 mice when compared to that detected in the 23-24 month-old mice. Thus, to 
clarify the cellular mechanisms and interplay of glial cells involved in local Aβ uptake and 
clearance, it was decided to focus on the younger cohort. Microglial activation and response 
to transplanted astrocytes and the involvement of microglia in the reduction of Aβ burden 
was examined by CD68 and CD45 immunohistochemistry. Staining for apoptotic cells was 
also carried out to shed more light on the viability of transplanted cells.  
CD68 is a marker indicating phagocytic activity especially in macrophages and 
microglia. After a two-month follow-up time, CD68 was significantly up-regulated in the 
hippocampi with the transplanted astrocytes compared to PBS injected APdE9 hippocampi 
(p < 0.01, Study II, Fig. 3A). Wild-type mice transplanted with astrocytes or injected with 
PBS showed similar, moderate CD68 immunostaining. This suggests that astrocyte 
transplantation as such does not induce CD68 up-regulation in microglia, but rather occurs 
with co-existing AD pathology. Indeed, microscopy revealed a close association between 
the microglial CD68 marker and transplanted eGFP expressing astrocytes (Study II, Fig. 3D) 
in the APdE9 brain but never in the wild-type brain (data not shown) suggesting that 
microglia were able to phagocytose some of the transplanted astrocytes. Similarly, after 
two-month follow-up time, CD45 immunoreactivity was up-regulated in APdE9 mice but 
not in wild-type mice transplanted with astrocytes (data not shown). Since CD45 is present 
in all mononuclear hematopoietic cells regardless of their phagocytic activity, the overall 
level of CD45 immunoreactivity was higher as compared to CD68 in APdE9 mice.  
Next, the development of microglial response to astrocyte transplantation and Aβ 
burden was assessed at different time points. After a two-week follow-up time, CD45 
positive microglia were found mostly within human Aβ deposits resembling the situation 
in intact APdE9 brain (Study II, Fig. 4B-D). At two months, most of the plaque-like 
structures had disappeared and CD45 positive microglia were surrounding the 
transplanted astrocytes colocalized with human Aβ (Study II, Fig. 4I-L). Examination at the 
one-month time point revealed an intermediary pattern where CD45 positive microglia 
were located within and around still intact Aβ deposits and also were surrounding the 
transplanted astrocytes (Study II, Fig. 4E-H)  
 The ability of transplanted astrocytes to internalize and induce the degradation of the 
human Aβ locally and the simultaneous, increased phagocytic activity of microglia and the 
microgliosis around the Aβ burdened astrocytes prompted an investigation of the viability 
of the grafted and endogenous cells at the two-month time point. Terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method 
together with Iba1 immunohistochemistry was applied to detect apoptotic cells in the area 
of transplanted eGFP astrocytes. Quantification of the eGFP signal colocalization with 
TUNEL staining revealed that, on average, 45 % of transplanted astrocytes in APdE9 
hippocampi were apoptotic (Study II, Fig. 5A-D), whereas only ~24 % of transplanted 
astrocytes were apoptotic in the wild-type brain, suggesting that the environment was 
determining the fate of the transplanted astrocytes. The colocalization of Iba1 was also 
examined with TUNEL to reveal apoptotic endogenous microglia. The amount of apoptotic 
microglia (less than 7 %) was noted to be increased by four-fold in APdE9 hippocampi 
compared to wild-type mice (Study II, Fig. 5E-H), suggesting that the Aβ-rich environment 
and Aβ burdened transplanted astrocytes may have induced apoptosis also in resident 
microglia. The amount of apoptotic resident astrocytes in APdE9 mice was low and 
comparable to PBS-injected APdE9 and wild-type mice.  
According to data from Study II, it seems that a large portion of Aβ-degrading 
transplanted astrocytes undergo apoptosis. However, genetically modified astrocytes could 
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survive longer and act as vehicles for Aβ degrading enzymes, drugs or even neurotrophic 
factors, as found in the study of Giralt et al. 2010 using modified astrocytes expressing 
brain-derived neurotrophic factor. 
5.4 INTRACELLULAR AND SECRETED PROTEASES ARE INVOLVED IN Aβ 
CLEARANCE BY ASTROCYTES 
Results obtained in the transplantation experiments confirmed the role of mature astrocytes 
as Aβ degrading cells under in vivo conditions. In an attempt to clarify the mechanisms 
involved in Aβ degradation, next it was decided to focus on proteases. The proteases 
expressed and subsequently also secreted by astrocytes are generally known to play an 
important role in Aβ clearance (Eckman et al. 2006; Iwata et al. 2000, 2004; Kehoe et al. 1999; 
Zou et al. 2007). However, the present view on the role of Aβ degrading proteases in the 
context of human, naturally deposited Aβ or in in vivo conditions is incomplete. In Study II, 
the expression of three Aβ catabolising proteases, NEP, ACE-1 and ECE-2 was analyzed. 
GFAP antibody was used to detect the transplanted and endogenous astrocytes, which 
could be further distinguished from each other based on eGFP fluorescence. The possible 
overlay of protease immunoreactivity with eGFP from transplanted astrocytes was 
examined using double immunohistochemistry. The results showed that all these proteases 
were expressed almost exclusively in transplanted astrocytes (Study II, Fig. 6C, D, G, H, K, 
L), suggesting that endogenous astrocytes do not participate in Aβ clearance by expressing 
proteases as efficiently as the transplanted, yet mature astrocytes. GFAP immunoreactivity 
also revealed significant endogenous astrocytosis resembling glial scarring around 
transplanted cells at the two months’ time point (Study II, Fig. 6B, D, F, H, J, L).  
To further survey the role of astrocytic Aβ degrading proteases, in vitro and ex vivo 
experiments were performed on similar eGFP expressing adult astrocytes as those used in 
in vivo experiments. The expression of NEP, ACE-1 and ECE-2 in eGFP astrocytes in vitro 
was examined by analysing the corresponding immunoreactivities in cells grown either in 
normal cell culture plates or on top of wild-type or APdE9 brain sections. Importantly, the 
protease expression was up-regulated in astrocytes in the presence of the brain sections 
(Study II, Fig. 7A). Especially NEP was significantly up-regulated in astrocytes grown on 
top of APdE9 sections compared to wild-type mouse brain sections (p < 0.05) suggesting 
that astrocytes rapidly respond to Aβ by up-regulating the degrading enzyme (Study II, 
Fig. 7A-C).  To assess the possible effect of these enzymes on Aβ degradation, an ex vivo Aβ 
clearance assay was performed by incubating eGFP expressing astrocytes in the presence or 
absence of inhibitors for NEP, ACE-1 or ECE-2 on top of APdE9 brain sections. After 24 h of 
co-incubation, the remaining Aβ burden was analysed from the sections (Study II, Fig. 7D). 
The results showed that adult eGFP astrocytes degraded human Aβ, which is in line with 
previous data. Inhibitors of NEP, ACE-1 and ECE-2 all significantly blocked the capacity of 
adult astrocytes to clear human Aβ (p < 0.05 for NEP and ACE-1 inhibitors, p < 0.01 for 
ECE-2 inhibitor). The data from Study II clearly indicates that the Aβ degrading proteases 
NEP, ACE-1 and ECE-2 are actively involved in Aβ clearance by astrocytes. In the CNS, 
these enzymes are mainly cell-membrane associated or alternatively intracellular (Table 2).  
These studies were further extended to clarify the contribution of astrocyte secreted 
proteases in synthetic Aβ1-42 clearance. Rather than examining the clearance of Aβ in the 
underlying section, the plain medium of astrocytes grown on top of Aβ containing or wild-
type brain sections was collected and plated on new wells containing synthetic, oligomeric 
human Aβ1-42. Human Aβ1-42 ELISA analysis was thereafter used to reveal potential Aβ1-42 
clearance by possibly secreted proteases present in astrocyte derived medium (astrocyte 
conditioned medium, ACM). Surprisingly, ELISA showed that the medium isolated from 
adult astrocytes grown on top of the APdE9 or wild-type mouse brain sections reduced the 
amount of synthetic Aβ by 97 % compared to non-astrocyte conditioned medium (plain 
culture medium incubated with Aβ1-42). In addition, medium collected from adult astrocytes 
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grown on normal cell culture plates efficiently reduced the amount of synthetic Aβ1-42. (Fig. 
8, unpublished data). Neonatal astrocytes are unable to degrade Aβ deposits from AD 
brain sections ex vivo. Surprisingly, medium collected from neonatal astrocytes grown on 
top of either APdE9 or wild-type sections significantly reduced the concentration of Aβ1-42. 
Conditioned medium from neonatal astrocytes grown on normal cell culture plates, 
however, was less efficient in clearing synthetic Aβ, as compared to ACM incubated with 
wild-type and APdE9 sections (Fig 8; p < 0.001). These preliminary data indicate that in 
addition to cell-associated proteases, the secreted forms of the enzymes capable of digesting 
Aβ1-42 participate in its clearance in vitro. Furthermore, these results confirm that data 
obtained with neonatal, the most widely used cell type in astrocyte research, in vitro 
experiments utilizing synthetic Aβ does not correlate with the behavior of these cells upon 
contact with naturally deposited human Aβ ex vivo or in vivo. 
  The studies were extended to clarify the identity of the secreted proteases. For this 
purpose, adult or neonatal astrocytes were cultured on top of the APdE9 brain sections, the 
medium was collected and incubated further with broad spectrum inhibitors for serine-, 
metallo- or cysteineproteases or aspartyl peptidases and synthetic Aβ1-42. Co-incubation of 
medium with serine protease inhibitor resulted in reduced disappearance of (p < 0.001) Aβ1-
42 by adult (60 % of Aβ1-42 not degraded) and neonatal (45 % of Aβ1-42 not degraded) medium 
(Fig. 9A, B, unpublished data). In addition, aspartyl peptidase (p < 0.01) and 
metalloproteinase (p  <  0.05) inhibitors seemed to have some impact on the degradation of 
Aβ1-42 by neonatal medium (Fig. 9B, unpublished data).  
The effect of the protease inhibitors on the viability of the astrocytes was examined by 
staining the treated cells with DAPI. Protease inhibitors had no effect on the viability of the 
cultured astrocytes (viability over 96 % for adult and neonatal astrocytes, data not shown) 
when compared to astrocytes incubated with medium only. 
 
 
Figure 8. The medium isolated from adult or neonatal mouse astrocytes incubated for 24 h on 
top of the Aβ-burdened APdE9 (TG section), wild-type brain section (WT section) or without the 
brain section was effective in degrading Aβ1-42 compared to medium that was not conditioned 
with astrocytes or sections.  
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Figure 9. The medium isolated from astrocytes grown on top of the APdE9 brain section for 24 h 
was further incubated for 24 h with broad spectrum inhibitors of serine, cysteine, aspartyl 
peptidase or metalloproteases and Aβ1-42. Serine protease inhibitor significantly inhibited (p < 
0.001) Aβ1-42 degradation by A) adult and B) neonatal astrocyte conditioned medium. In 
addition, metalloprotease and aspartyl peptidase inhibitors had a minor, but significant effect on 
Aβ1-42 degradation by neonatal astrocyte medium. 
5.5 GENE EXPRESSION DIFFER BETWEEN ADULT AND NEONATAL 
ASTROCYTES INCUBATED ON TOP OF THE APdE9 OR WILD-TYPE MOUSE 
BRAIN SECTIONS 
Studies I and II show the capability of adult astrocytes to degrade Aβ and suggest some of 
the molecular mechanisms included in this process. The overall change in gene expression 
in astrocytes during Aβ degradation is presently still unknown. In addition, although much 
less responsive to Aβ as compared to adult astrocytes, neonatal astrocytes still are able to 
internalize Aβ deposits in vivo (Study I) and secrete synthetic Aβ1-42 degrading proteases 
outside the cell (unpublished data). Due to gross differences between adult and neonatal 
astrocytes, it was of interest to compare their gene expression after exposure to Aβ-
burdened brain sections while wild-type brain sections served as controls. 
In Study III, neonatal and adult astrocytes were incubated on top of APdE9 or wild-type 
mouse brain sections for 24 h, in similar conditions than in other ex vivo Aβ clearance assays 
in other studies of this thesis. The purpose of this experiment was to examine the changes 
in gene expression in response to different section types. The astrocytes were carefully 
detached from the sections and mRNA was isolated. After the quality control of the mRNA 
and gene expression analysis by Affymetrix, the data were compared to published 
microarray data sets of highly purified astrocytes, neurons and oligodendrocytes (Cahoy et 
al. 2008). The comparison determined the purity of the collected cells as in vivo purified 
adult astrocytes and in vitro cultured neonatal astroglia (Study III, Fig. 2). 
The gene expression profiles were then compared between the astrocytes isolated from 
the top of the wild-type and transgenic APdE9 brain sections. In all, 877 genes in adult and 
132 genes in neonatal astrocytes were differentially expressed by two fold or more (Study 
III, Fig. 3A).  In Study III, up-regulation indicates that gene expression of isolated astrocytes 
was higher in APdE9 brain section compared to wild-type section, down-regulation 
conversely.  With regard to the astrocytes cultured on top of the APdE9 sections, one third 
of the differentially expressed genes were up-regulated both in adult and neonatal 
astrocytes. However, only 13 genes of the up-regulated and 30 genes of the down-regulated 
genes were the same between the adult and neonatal astrocytes. The genes with altered 
expression were classified with Gene Ontology (GO) annotations, based on their cellular 
function (Study III, Fig. 3B-E). Adult astrocytes grown on top of the APdE9 sections up- and 
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down-regulated approximately similar number of genes related to catalytic and hydrolase 
activity when compared to neonatal astrocytes, but peptidase, scavenger receptor and 
glutathione activities were notably up-regulated (Study III, Fig. 3B, 4A). Importantly, the 
latter up-regulated functions in adult astrocytes are related to the enhancement of Aβ 
clearance and reduction of its toxicity. Accordingly, a specific down-regulation of several 
peptidase inhibitors occurred in adult astrocytes grown on top of the APdE9 section when 
compared to the wild-type section (Study III, Fig. 4A). In addition, neonatal astrocytes 
revealed down-regulated peptidase inhibitor gene expression, but there was no specifically 
enriched peptidase or protease group in neonatal astrocytes grown on top of the APdE9 
brain sections (Study III, Fig. 3E, 4B). GO class transferase activity was highly enriched in 
down-regulated genes by  neonatal astrocytes (Study III, Fig. 3E) and most of those genes 
were related to cholesterol synthesis (Study III, Fig. 4B). Neonatal astrocytes up- and down-
regulated several genes were associated with endocytosis (Study III, Fig. 4B), e.g. Aβ 
endocytosing macrophage scavenger receptor 1 (Msr1) (Paresce et al 1996). Adult astrocytes 
had more enriched GO classes of altered genes compared to neonatal astrocytes, e.g. classes 
related to polysaccharide binding, cytokine receptor binding, zinc ion binding, 
transcription regulator activity, kinase activity, DNA binding, calcium ion binding and 
growth factor activity. Neonatal astrocytes showed less GO clusters: cytokine activity, 
structural constituent of myelin sheath, heme binding, iron ion binding (data not shown).  
5.5.1 mRNA quantification by qRT-PCR 
The results from the microarray analysis were confirmed by analyzing the expression of 13 
genes by qRT-PCR. The genes possibly associated with Aβ clearance were selected by 
observing differences and similarities between adult and neonatal expression profiles and 
using GO analysis and literature. The genes with very low expression according to 
microarray results were excluded from further study. For example, cathepsin S (Ctss) had a 
very high fold change but the expression level was extremely low and thus was excluded.  
Remarkably, scavenger receptor class A, member 5 (Scara5) was up-regulated by 200 
fold in adult astrocytes grown on transgenic APdE9 brain section. This receptor is known to 
mediate phagocytosis of bacterial material and ferritin bound iron (Jiang et al. 2006; Li et al. 
2009). Scara5 was expressed at extremely low levels in neonatal and adult astrocytes grown 
on wild-type brain sections.  
Apolipoprotein E (Apoe) is the major susceptibility gene for AD (Bertram et al. 2010; 
Rebeck et al. 1993; Strittmatter et al. 1993). In the present study, adult astrocytes were up-
regulated Apoe by over 3 fold, but down-regulation in neonatal astrocytes was only 
confirmed by qRT-PCR. Interestingly, the expression of Apoe was 10 times higher in 
neonatal compared to adult astrocytes grown on transgenic APdE9 brain sections (III, Fig. 
5). Furthermore, neonatal astrocytes down-regulated the cholesterol synthetizing enzymes 
3-hydroxy-3-methylglutaryl-CoA synthase 1 (Hmgcs1) and 24-dehydrocholesterol 
reductase (Dhcr24) to the same extent as Apoe (III, Fig. 5). 
The phosphate regulating gene with homologies to endopeptidases on the X 
chromosome (Phex) degrades synthetic Aβ1-40, although to a minor extent (Shirotani et al. 
2001). Adult astrocytes grown on APdE9 brain sections had up-regulated Phex by over 10 
fold, whereas the expression by neonatal astrocytes was very low (III, Fig. 5). A member of 
the high temperature requirement family of serine proteases (Htra1) decreased Aβ levels in 
vitro and in cell cultures (Grau et al. 2005; III, Fig. 5). HtrA serine peptidase 1 (Htra1) was 
expressed both by adult and neonatal astrocytes moderately. However, only adult 
astrocytes grown on ApdE9 sections up-regulated this protease compared to astrocytes 
grown on wild-type sections. From all Aβ degrading matrix metallopeptidases, neonatal 
astrocytes expressed a very high level of matrix metallopeptidase 9 (Mmp9; data not 
shown). Quantitative RT-PCR confirmed significant up-regulation of Mmp9 in both adult 
and neonatal astrocytes cultured on top of the APdE9 section compared to astrocytes 
cultured on top of the wild-type sections (III, Fig. 5).  
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6 Discussion 
The inestimable complexity of AD poses remarkable challenges for research into this 
common neurodegenerative disease, but it does appear that there are several important 
factors now recognized as being crucial to the development of AD. However, the separation 
of the true causes and effects and the identification of the ultimate triggers for the disease 
have remained obscure. 
Glial cells have many roles in the brain e.g. in the maintenance of the homeostasis and 
they also function as immunomodulators in the CNS, but on the other hand these cells may 
also induce many potentially harmful effects through overproduction of proinflammatory 
cytokines and chemokines which may ultimately lead to the death of the surrounding 
neurons. In humans, there are about 80-90 billion glial cells and an approximately equal 
amount as neurons (86 billion) but these cells are not evenly distributed in the brain 
(Azevedo et al. 2009). If one consideres the glia cells in the human brain, about 75 % are 
oligodendrocytes, 20 % astrocytes and 5 % microglia (Pelvig et al. 2008). The maintenance 
of the normal physiology of glial cells, including astrocytes is critical for the proper 
functions of neurons in the CNS.  
Neuroinflammation may also contribute to the pathogenesis of AD, as the increased 
neuroinflammatory components are clearly interrelated with Aβ pathology. Aging also 
exposes an individual to spontaneous mutations in the DNA and aged cells have a slower 
regeneration capacity. In addition to these endogenous reasons, exogenous factors (e.g. 
head trauma, viruses, environmental toxic agents, life style) have been suggested to act as 
potential factors contributing to the generation of the AD. 
Mice are the most widely used animal species in preclinical research. However, it is well 
known that the results obtained from the animal models are often poorly translated into 
clinical studies in any neurological disease. Different mouse strains may provide different 
results. Likewise, the gender differences often influence the progression of the disease. 
Thus, the results of the studies like this thesis can not be directly generalized to the human 
biology, but nevertheless these preclinical observations are valuable as they shed light on 
complex biochemical mechanisms and may provide new ideas for e.g. drug discovery 
purposes. The mouse models used in this thesis were the “golden-standard” models and 
therefore suitable for preclinical AD research. 
 
The purpose of the present thesis was to expand understanding on the functional role of 
the main glial cell type around neuronal cell bodies, astrocytes, in AD relevant conditions. 
The main observations of the thesis show that:  
I) Adult mouse astrocytes degrade Aβ from human post-mortem AD brain sections ex 
vivo and astrocytes isolated from both neonatal and adult astrocytes colocalize with and 
internalize human Aβ in the hippocampus of APdE9 mice.  
II) After two months of follow-up, adult mouse astrocytes transplanted into the 
hippocampi of APdE9 mice induce significant local degradation of Aβ deposits compared 
to PBS injected APdE9 mice. The Aβ burden is reduced more efficiently in younger APdE9 
mice compared to APdE9 mice aged 23-24 months. Grafts of exogenous adult astrocytes 
undergo apoptosis after degradation of Aβ. However, the transplantation activates also 
microglia, which seem to participate in Aβ clearance actively by phagocytosing the Aβ 
burdened, apoptotic transplanted astrocytes.  
III)  The expression of proteases NEP, ACE-1 and ECE-2 is notably increased in 
transplanted adult astrocytes associated with Aβ deposits in vivo when compared to nearby 
resident cells or the adult astrocytes transplanted into wild-type mouse brain. Inhibition of 
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the same proteases in adult astrocytes incubated on top of the Aβ-burdened brain sections 
ceased their Aβ degrading capacity. Furthermore, unstimulated adult and neonatal 
astrocytes secrete proteases effective in degrading synthetic Aβ1-42 in vitro. When stimulated 
beforehand with Aβ-burdened brain sections, both adult and neonatal astrocytes secrete 
notable amounts of Aβ1-42 degrading serine proteases and neonatal astrocytes also released 
Aβ1-42 degrading metalloproteases and aspartyl peptidases.  
IV) Adult and neonatal astrocytes showed significant differences in the gene expression 
profiles when they were grown on top of Aβ-burdened or wild type mouse brain sections. 
In particular, significant up-regulation of genes related to peptidase, scavenger receptor 
and glutathione transferase activity in adult astrocytes cultured on top of the Aβ-burdened 
sections were observed. qRT-PCR analysis confirmed the alterations in gene expression of 
key Aβ degrading peptidases, scavenger reseptors and cholesterol synthesis. 
6.1 REACTION OF ADULT AND NEONATAL MOUSE ASTROCYTES TO Aβ 
EX VIVO AND IN VIVO 
Study I used ex vivo assay to reveal that cultured adult mouse astrocytes were able to 
degrade Aβ deposits present in human post-mortem AD brain tissue, but this was not the 
case with neonatal astrocytes. This is in line with previous data regarding human Aβ 
degrading capacity of adult and neonatal astrocytes ex vivo, with the exception that mouse 
brain sections with deposited human Aβ were used (Koistinaho et al. 2004; Wyss-Coray et 
al. 2003).  
Next, the capacity of astrocytes to colocalize with and degrade Aβ was examined in vivo, 
and the results showed that adult but interestingly, also neonatal astrocytes could 
internalize human Aβ deposits already after 1-7 d in APdE9 mouse brain, albeit the Aβ 
internalization by neonatal astrocytes was less effective as compared to adult astrocytes. It 
seems likely that developing neonatal astrocytes require the cross-talk with other cell types 
in the brain and thus respond to Aβ deposits only under in vivo conditions. Still the 
internalization in vivo is less efficient than in adult astrocytes, suggesting that these cells 
might not yet have developed fully functioning mechanisms for the recognition and 
internalization of Aβ. In addition, the difference in chemical structure of Aβ deposits 
between transgenic AD mouse models and human AD brain may have effects on the Aβ 
degradation capacity of neonatal astrocytes. Human Aβ deposits develop stronger 
resistance to chemical and physical disruption compared to Aβ deposits in mouse brain, 
due to covalently linked dimers and various post-translational modifications (Higgins et al., 
1995; Kalback et al., 2002; Kuo et al., 2001) and numerous glycoproteins and glycolipids 
(Roher et al. 1993; Selkoe et al. 1986). Furthermore, Aβ plaques deposited in mouse brain 
may be more than twice as extensive the size of the plaques in human brain, despite the fact 
that human plaques usually require decades to develop compared to months in mice (Kuo 
et al. 2001). In addition, aging of human fetal astrocytes in vivo, but not in vitro, change the 
expression of e.g. α- and β-chemokines (Bakhiet et al. 2002). This affects the differentiation, 
proliferation and migration of these cells. All these previous studies provide possible 
explanations regarding the unresponsiveness of neonatal astrocytes to Aβ deposits in ex 
vivo conditions and the unexpectedly increased association with Aβ deposits in vivo.   
6.2 TRANSPLANTED ADULT MOUSE ASTROCYTES INDUCE 
DEGRADATION OF Aβ IN AD MOUSE MODEL, BECOME APOPTOTIC AND 
ACTIVATE PHAGOCYTIC MICROGLIA 
Based on the results from Study I revealing for the first time the capacity of eGFP adult and 
neonatal astrocytes to internalize human Aβ convincingly in vivo, the in vivo approach used 
in Study II was continued by extending the follow-up time up to two months. For this 
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purpose, we transplanted only adult eGFP mouse astrocytes, which in Study I appeared to 
be more effective in internalizing Aβ deposits in vivo and monitored their Aβ degradation 
capacity. The results revealed that Aβ burden was significantly decreased in the area where 
transplanted astrocytes were migrated. The reduction was more efficient when the 
astrocytes were transplanted in the younger mice aged 12 months, where the Aβ plaques 
are still developing into a fibrillar form, compared to 23-24 months old mice which showed 
denser and thioflavin S positive Aβ deposits. This is in line with the observations in which 
primary human astrocytes and microglia were able to bind and ingest Aβ1-42 in vitro but that 
astrocytes were more prone to take up oligomeric Aβ rather than its fibrillar form (Nielsen 
et al. 2009, 2010). 
In study II, the reduction in the amount of Aβ1-40 and Aβ1-42 was also determined by 
ELISA from the hippocampal tissues isolated from the astrocyte transplanted or PBS-
injected APdE9 mice. The results showed that the levels of total hippocampal Aβ1-40 and 
Aβ1-42 were both reduced by ~ 10 % in APdE9 mice transplanted with adult astrocytes 
compared to PBS-injected APdE9 mice. This trend supported the findings obtained from 
immunohistochemical studies, but the difference was not significant (data not shown) and 
provided no meaningful conclusions on ELISA data. The area with transplanted astrocytes 
represents only about 0.13 mm3 within the hippocampus. Since it is impossible to sample 
0.13 mm3 volumes of brain tissue with high anatomical accuracy, it can be concluded that 
the sensitivity of ELISA is not sufficient for detecting the changes in Aβ burden in areas 
with transplanted astrocytes. 
After longer transplantation times (~2 - 8 months), astrocytes have been shown to remain 
viable and actively migrating, without inducing significant gliosis or infiltration of 
leucocytes (Azizi et al. 1998; Selkirk et al. 2002). In Studies I and II, the astrocytes did not 
degenerate or die after the 24-hour incubation on top of human AD, mouse APdE9 or wild-
type brain sections. During in vivo experiments (Studies I and II), viable astrocytes 
colocalized with Aβ deposits after short periods (1-2 weeks) of transplantation, but after 
longer follow-up time (two months, Study II), as much as 45 % of the transplanted 
astrocytes in the APdE9 brain showed more granular and degraded morphology and were 
apoptotic based on the results from TUNEL immunohistochemistry. The longer 
transplantation time in Aβ burdened environment is probably toxic to the transplanted 
astrocytes, as only 24 % of transplanted astrocytes were TUNEL-positive in wild-type mice. 
Transplantation into the aged and structured brain itself may induce cell death to some 
extent, but the cells collected from the same cellular batch in vitro managed notably very 
differently when transplanted into an Aβ burdened brain as compared to their properties in 
the wild-type mouse brain. Transplanted astrocytes internalized Aβ in the APdE9 mouse 
hippocampus, causing possibly the apoptosis of these cells e.g. due to mitochondrial failure 
and oxidative stress, similarly to previous studies showing the ability of Aβ to cause 
potentially harmful oxidative stress in microglia and astrocytes (Abramov et al. 2004; Zhu 
et al. 2006). In addition, the results in Study III suggested that adult astrocytes incubated on 
top of the APdE9 brain sections, significantly up-regulated glutathione transferase activity, 
which is an antioxidant usually highly expressed by astrocytes during pathology (Dringen 
et al. 2000). Under certain cell culture conditions, Aβ exposure is known to result in 
vacuolization (Nuutinen et al. 2007) or even death of astrocytes (Rodrigues et al. 2000; 
Takuma et al. 2004) and death of astrocytes has also been described in AD patients 
(Kobayashi et al. 2004; Takuma et al. 2004).  
Interestingly, microglia seemed to phagocytose the transplanted, dying astrocytes. In 
addition, regardless of the low percentage of the apoptotic microglia, it is important to note 
that the number of apoptotic microglia was four times higher in APdE9 brain compared to 
wild-type mouse brain transplanted with eGFP expressing astrocytes, suggesting that the 
Aβ-rich environment and associated Aβ degradation by transplanted astrocytes may have 
induced apoptosis in nearby resident microglia. The resident GFAP positive astrocytes also 
remained viable in the vicinity of the transplanted astrocytes. Thus, in addition to their 
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various important functions during AD pathology, activated microglia may also clear Aβ-
burdened astrocytes. 
It can be hypothesized that the astrocytes existing in the aged, Aβ rich brain may not be 
able to respond any longer to the ongoing formation of Aβ deposits in contrast to healthy, 
but mature astrocytes. The function of endogenous astrocytes may decline with advancing 
age and increasing Aβ pathology in AD brain. In aged brain, the inflammatory state with 
hyperactivated immunoresponsive glial cells and accumulating toxic forms of Aβ may 
ultimately block the Aβ clearing capacity of resident astrocytes. The chemotactic and 
inflammation also related signaling between microglia and activated astrocytes may be 
reduced in older mice (Tanuma et al. 2006) and the normal function of Aβ degrading 
proteases maintaining the balance in Aβ production and clearance in health have been 
shown to be affected in AD (De Strooper 2010). Considering these observations it was also 
noted in Study II that the expression of NEP, ECE-2 and ACE-1 in the resident astrocytes 
was very negligible compared to transplanted adult astrocytes associated with Aβ deposits. 
Another possible mechanism is the altered composition of amyloid associated proteins in 
mature plaques that affects their clearance (Nielsen et al. 2010).  
6.3 NEP, ACE-1 AND ECE-2 DEGRADE Aβ EX VIVO IN ADULT 
ASTROCYTES 
Aβ formed in the brain is degraded by multiple pathways under normal physiological Aβ 
metabolism. Astrocytes express and secrete many proteases with recognized Aβ degrading 
functions (Eckman et al. 2006; Iwata et al. 2000, 2004; Kehoe et al. 1999; Zou et al. 2007). 
Study II focused on the analysis of three major astrocytic proteases known to be involved in 
Aβ catabolism, namely NEP, ACE-1 and ECE-2. Selective inhibitors for these proteases 
significantly blocked Aβ degradation by adult astrocytes cultured on top of the APdE9 
brain sections, compared to astrocytes incubated without inhibitors. These proteases are 
mainly cell membrane-associated or intracellular in the CNS (Table 2), suggesting that the 
Aβ is degraded by transplanted adult astrocytes mainly intracellularly.  
At two months time point, the same proteases were also concentrated almost exclusively 
within the eGFP adult astrocytes transplanted into APdE9 mouse hippocampus as 
discussed above. Previous results have shown that NEP, ACE-1 and ECE-2 are localized in 
astrocytes of AD patients and transgenic AD mice (Dorfman et al. 2010; Eckman et al. 2001, 
2006; Hu et al. 2001; Iwata et al. 2000, 2004; Kanemitsu et al. 2003; Palmer et al. 2009; Zou et 
al. 2007), but according to these observations, these proteases were almost exclusively 
expressed in Aβ-associated transplanted astrocytes, whereas the expression in endogenous 
astrocytes was much weaker and scattered throughout the brain parenchyma. However, it 
has been unclear whether these enzymes function mainly intracellularly or through 
endocytosis. In addition, these proteases are not exclusively involved in the degradation of 
Aβ alone, but they perform multiple other, more general tasks (e.g. functioning as 
vasopeptidases).  
However, both adult and neonatal astrocytes naturally secreted efficient synthetic Aβ1-42 
degrading proteases outside the cell, even without the contact with underlying Aβ-
burdened or wild-type brain sections. The serine protease family seems to be the most 
efficiently secreted, Aβ1-42 degrading protease family both in adult and in neonatal 
astrocytes. The microarray data (Study III) support these results by showing that several 
protease inhibitors, including some serine protease inhibitors, were down-regulated in both 
adult and neonatal astrocytes incubated on top of the APdE9 brain section compared to 
incubation with wild-type sections  (Study III, Fig. 4B).  
In addition to inhibiting a number of other serine proteases, one of the most frequently 
used agents, 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) inhibits also plasmin 
(Mintz et al. 1993), which also has been shown to degrade Aβ and block its toxicity (Tucker 
et al. 2000). Plasminogen is a pre-stage protein prior to the formation of plasmin and in 
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addition to neurons and microglia, also in astrocytes, a plasminogen activator-like activity 
has been observed. Interestingly, Aβ1-42 induces this activity in astrocytes (Lee et al. 2007).  
Furthermore, neonatal astrocytes secreted metalloproteases and aspartyl peptidases 
outside the cell capable to some extent of degrading synthetic Aβ1-42 when stimulated with 
Aβ-burdened brain sections. Neonatal astrocytes are however unable to degrade human Aβ 
deposits from tissue (Koistinaho et al. 2004). This discrepancy most likely is due to the 
major difference in the nature and composition of Aβ used. Synthetic Aβ1-42 differs from 
human Aβ deposited in tissue in multiple ways. For example synthetic Aβ aggregrates lack 
the co-deposited proteins, such as ApoE, that may be involved in astrocytic clearance of Aβ. 
The folding and aggregation of synthetic Aβ most likely also differs from that of mature Aβ 
plaques that have developed in vivo over several months in mice or decades in human.  
These data further suggest that adult and neonatal astrocytes have distinct mechanisms for 
the degradation of proteins and further underlines the importance of careful selection of the 
cell type and Aβ used in in vitro experiments.  
Even though the results showed a significant role in Aβ1-42 clearance for the main 
secreted, Aβ1-42 degrading protease families from adult and neonatal astrocytes, the exact 
identity of these secreted proteases is still unknown. In addition, the capacity of secreted 
proteases to degrade Aβ deposits in vivo is still far from clear. Even if the proteases secreted 
from neonatal astrocytes have a substantial role in the degradation of synthetic Aβ1-42, 
neonatal astrocytes cannot degrade Aβ deposits during ex vivo conditions i.e. they lack a 
mature degrading mechanism for Aβ deposits whether they were secreted or cell-
associated. Understanding these key differences between neonatal and adult astrocytes 
may also reveal the mechanisms through which production of intracellular and secreted Aβ 
degrading proteases could be boosted, for example for therapeutic purposes.  
Previously, different fragments of Aβ1-42 have been shown either inhibit Aβ induced cell 
death or promote it (Numata and Kaplan 2010). Based on the studies from the field and the 
present results, astrocytes degrade Aβ using multiple proteases. All these enzymes have 
different substrate specificities and cleavage sites, so one may assume that during non-
pathogenic conditions optimally functioning astrocytes may cleave Aβ to small fragments. 
In this study, the different Aβ degradation products were not identified. Further studies are 
needed to clarify the characteristics and toxicity of the different Aβ degradation products 
generated by astrocytes, for example their influence on neurotransmission. 
6.4 Aβ ALTERS GENE EXPRESSION PROFILE ESPECIALLY IN ADULT 
ASTROCYTES EX VIVO 
Neonatal astrocytes differ from adult astrocytes in many ways, and their complete 
maturation to the adult phenotype most probably requires interactions with other brain 
cells in vivo. The findings of Study III indicated that the response of neonatal astrocytes 
against Aβ is more passive ex vivo compared to adult astrocytes. The up-regulated genes in 
adult astrocytes related into specific Aβ degrading proteases, scavenger receptors and 
glutathione synthesis confirms their more mature response to Aβ clearance. 
According to microarray analysis in Study III, four scavenger receptors and 18 
peptidases / proteases were up-regulated and five peptidase / protease inhibitors were 
down-regulated in adult astrocytes, whereas neonatal astrocytes down-regulated six 
peptidase / protease inhibitors when cultured on APdE9 brain tissue ex vivo. In Study III, no 
changes were observed in gene expressions of the specific Aβ degrading proteases (NEP, 
ACE-1, ECE-2). However, the activity of these proteases could well increase even though 
the gene expression level remains unchanged, for example by post-translational 
modifications or changes in endogenous inhibitors or activators (Cabrol et al. 2009). 
Overall, the involvement of certain up-regulated genes in Aβ clearance is still unclear and 
only some of them were confirmed by qRT-PCR. 
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Scara5, a member of the scavenger receptor type A family, was remarkably up-regulated 
in adult astrocytes grown on top of APdE9 brain sections. Scavenger receptors are localized 
on the cell surface and scavenger receptor type A family mediates endocytosis of synthetic 
Aβ, also in neonatal mouse astrocytes (Alarcón et al. 2005; Allaman et al. 2010; Paresce et al. 
1996; Nakamura et al. 2006), but its role in human Aβ uptake by adult astrocytes has not 
been previously determined. Scara5 has been found to endocytose ferritin bound iron (Li et 
al. 2009), which is further attached to Aβ deposits in AD (Baruch-Suchodolsky et al. 2008; 
Faller and Hureau 2009), so Scara5 possibly clears Aβ from the extracellular space together 
with free iron.  This interaction may be disturbed by fucoidan and polyinosinic acid, which 
are also known to be ligands for scavenger receptors (Alarcón et al. 2005; Allaman et al. 
2010; Wyss-Coray et al. 2003) 
The peptidase Phex (phosphate regulating gene with homologies to endopeptidases on 
the X chromosome) and protease Htra1 (a member of high temperature requirement family 
of serine proteases) decrease Aβ levels in vitro (Grau et al. 2005; Shirotani et al. 2001). In 
Study III, both genes were up-regulated in adult but not neonatal astrocytes grown on top 
of APdE9 sections, suggesting that they may be involved in Aβ degradation by adult 
astrocytes.  
In addition to the Aβ degrading proteases (NEP, ACE-1 and ECE-2) observed in adult 
astrocytes in Study II, also oligomeric Aβ1-42 degrading extracellular proteases were secreted 
both by adult and neonatal astrocytes after incubation with Aβ-burdened brain section. In 
Study III, a significant down-regulation of a serine- and cysteine protease inhibitor 
Serpinb1a was detected both in adult and neonatal astrocytes. Similarly, this inhibitor may 
have been down-regulated in situations where the secretion of Aβ1-42 degrading serine 
proteases was increased both in adult and neonatal astrocytes cultured on APdE9 brain 
sections (unpublished data). However, this down-regulation of Serpinb1a and many of the 
other serine protease inhibitors observed in Study III were not confirmed by qRT-PCR, but 
it is tempting to hypothesize that the serine protease inhibitors had been significantly 
down-regulated especially in adult astrocytes, for example serine-type endopeptidase 
inhibitors Serpinb1a (intracellular) and Itih2 (extracellular), may be involved in Aβ 
degradation. 
The uptake and clearance of Aβ are ApoE-dependent in adult astrocytes (Koistinaho et 
al. 2004), but in Study III, adult astrocytes expressed notably lower levels of ApoE 
compared to neonatal astrocytes. Probably adult astrocytes compensate for the low 
expression level of ApoE by recycling it by an ApoE-isoform dependent mechanism 
(Heeren et al. 2004). Study III suggests that the overall expression level of apoE is not the 
limiting factor preventing neonatal astrocytes from clearing Aβ. ApoE is most likely needed 
for Aβ internalization by astrocytes via LDL receptors or LRP. However, ApoE may not be 
required for Aβ degradation per se. This is supported by the fact that neonatal astrocytes 
can internalize Aβ in vivo (Study I), but their capacity for degrading it is limited compared 
to adult astrocytes.  
Glial cells produce cholesterol by de novo synthesis in the brain. Brain ApoE mediates 
cholesterol transport to neurons by forming HDL particles (Gong et al. 2007; Ito et al. 1999; 
Krimbou et al. 2004). Overall, possible alterations in cholesterol metabolism have been 
suggested to occur in AD. In the study of Canepa et al. (2011), Aβ1-42 inhibited the 
expression of some cholesterol transporters and down-regulated the cholesterol synthesis 
in cultured neonatal astrocytes (Canepa et al. 2011). In Study III, neonatal astrocytes grown 
on APdE9 sections down-regulated apoE and Dhcr24 as well as Hmgsc1 involved in 
cholesterol synthesis. Several cholesterol synthesis-associated genes were also down-
regulated in adult astrocytes cultured on APdE9 sections. These data further demonstrate 
that multiple mechanisms, which may be linked to each other, regulate the capacity of 
astrocytes to recognize and degrade Aβ. 
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7 SUMMARY AND CONCLUSIONS 
The overall aim of the present thesis was to clarify the role of astrocytes as Aβ degrading 
cells in AD. Ex vivo, in vitro and in vivo techniques were used to assess the mechanisms and 
Aβ degrading capacity of astrocytes and to understand the interplay between astrocytes 
and microglia in experimental models of AD.  
 
The following results were obtained: 
 
1. Adult mouse astrocytes were able to degrade human Aβ deposits from post-mortem 
AD brain tissue. Neonatal astrocytes lack this Aβ degrading capacity in ex vivo 
conditions.  
2. After a few days’ follow-up time, both adult and neonatal astrocytes internalized Aβ 
deposits in vivo when transplanted into Aβ burdened hippocampi of transgenic 
APdE9 mice. After the two months’ follow-up time, transplanted adult astrocytes 
had degraded the majority of the Aβ deposits locally in the hippocampi of APdE9 
mice, become apoptotic and activated CD45 and CD68 immunoreactive microglia 
nearby. CD68 immunopositive microglia seemed to be able to phagocytose the Aβ 
burdened transplanted astrocytes. The astrocytes transplanted into wild-type mice 
remained alive and induced only minor CD45 immunoreactivity in microglia. 
However, despite the significantly increased microglial activation in astrocyte 
transplanted APdE9 mice, only a small amount of apoptotic endogenous microglia 
or astrocytes were observed, suggesting that enhanced microglial activation in AD 
play a significant role also in the clearance of Aβ-burdened astrocytes. 
3. Proteases neprilysin, angiotensin-converting enzyme-1 and endothelin-converting 
enzyme-2 were noted to be expressed by adult astrocytes also in vivo. These 
proteases were involved in Aβ degradation as their inhibitors significantly decreased 
Aβ clearance by adult astrocytes ex vivo.   
4. The gene expression profiles from adult and neonatal astrocytes cultured on top of 
the APdE9 or wild-type mouse brain sections revealed that due to the presence of 
Aβ in the brain section, the change of the phenotype and the number of genes with 
altered expression was notably greater in adult astrocytes as compared to neonatal 
astrocytes. In adult astrocytes, the up-regulated expression in specific genes related 
to Aβ degradation and endocytosis and anti-oxidative function, and qRT-PCR 
analysis confirmed the alteration in gene expression of key Aβ degrading peptidases, 
scavenger reseptors and cholesterol synthesis. In general, adult astrocytes seem to 
response sensitively to stress induced by Aβ when compared to neonatal astrocytes. 
Due to their mature response towards Aβ exposure, adult astrocytes would appear 
to represent a more relevant model for AD compared to neonatal astrocytes and thus 
may reveal new targets for therapeutic use in the future. 
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